[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 976
6. Mücke T, Tannapfel A, Kesting MR, Wagenpfeil S, Robitzky LK, Wolff KD, Hölzle F: Adenoid cystic carcinomas of minor salivary glands. Auris Nasus Larynx; 2010 Oct;37(5):615-20
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinomas of minor salivary glands.
  • OBJECTIVES: Adenoid cystic carcinoma (ACC) is a very rare epithelioid tumor with different prognostic factors relating to overall survival.
  • This study aims to analyze the prognostic factors, outcome and the value of surgical therapy on recurrent disease.
  • RESULTS: 64% of patients had a low-grade and 36% had a high grade disease.
  • [MeSH-major] Carcinoma, Adenoid Cystic / diagnosis. Neoplasm Recurrence, Local / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Lymph Nodes / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Neck Dissection. Neoplasm Staging. Prognosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20181451.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


7. Guo XL, Sun SZ, Wei FC: [Mechanisms of p16 gene inactivation salivary adenoid cystic carcinoma]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2005 Oct;23(5):418-20
Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mechanisms of p16 gene inactivation salivary adenoid cystic carcinoma].
  • OBJECTIVE: To study the mechanism of p16 gene inactivation in salivary adenoid cystic carcinoma.
  • METHODS: 53 cases of freshly excised salivary adenoid cystic carcinomas were studied.
  • Polymerase chain reaction (PCR) and single-stranded conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP) were used to detect deletion and mutation of p16 gene in salivary adenoid cystic carcinomas.
  • RESULTS: The homozygous deletion, mutation and hypermethylation of p16 gene were noted in 16 cases (30.2%), 4 cases (7.5%) and 26 cases (49.1%) respectively in 53 cases of salivary adenoid cystic carcinomas.
  • CONCLUSION: The main inactivation mechanisms of p16 gene in salivary adenoid cystic carcinoma were hypermethylation and homozygous deletion.
  • The mutation p16 gene was rare in salivary adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic. DNA Methylation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285551.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Mastropasqua MG, Maiorano E, Pruneri G, Orvieto E, Mazzarol G, Vento AR, Viale G: Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast. Mod Pathol; 2005 Oct;18(10):1277-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity for c-kit and p63 as an adjunct in the diagnosis of adenoid cystic carcinoma of the breast.
  • Adenoid cystic carcinoma of the breast represents a unique clinicopathologic entity with a variable histological appearance and a relatively indolent clinical course in most of the cases.
  • Adenoid cystic carcinoma may be difficult to differentiate from infiltrating duct carcinomas, and in particular from tubular and cribriform carcinomas, especially in core or vacuum-assisted biopsies.
  • We evaluated the prevalence of c-kit, p63, and e-cadherin immunoreactivity in a series of 20 adenoid cystic carcinomas, comparing the results with those obtained in a series of infiltrating tubular carcinomas and infiltrating cribriform carcinomas.
  • Three (15%) adenoid cystic carcinomas and all infiltrating tubular and cribriform carcinomas showed estrogen receptor and/or progesterone receptor immunoreactivity (P < 0.00001 for estrogen and P = 0.00002 for progesterone receptors).
  • Adenoid cystic carcinomas consistently lacked any immunoreactivity for HER/2, whereas three (15%) infiltrating and cribriform carcinomas showed weak and incomplete membrane staining (P = 0.23077).
  • Membranous immunoreactivity for c-kit was found in all except one (predominantly basaloid) adenoid cystic carcinomas (95%), and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • Nuclear immunoreactivity for p63 was found in all except three (predominantly basaloid) adenoid cystic carcinomas (85%) and in none of the infiltrating tubular and cribriform carcinomas (P < 0.00001).
  • All infiltrating tubular and cribriform carcinomas and 18/20 (90%) adenoid cystic carcinomas showed immunoreactivity for e-cadherin (P = 0.48718).
  • In summary, adenoid cystic carcinomas showed the following phenotype: estrogen receptor-/progesterone receptor-/c-kit+/p63+ (13 cases, 65%), estrogen receptor-/progesterone receptor/c-kit+/p63- (three cases, 15%), estrogen receptor-/progesterone receptor-/c-kit-/p63+ (one case, 5%), estrogen receptor+/progesterone receptor+/c-kit+/p63+ (two cases, 10%), and estrogen receptor+/progesterone receptor-/c-kit+/p63+ (one case).
  • By contrast, all the infiltrating tubular and cribriform carcinomas showed the estrogen receptor+/progesterone receptor+/c-kit-/p63- phenotype.
  • Our data provide evidence that immunoreactivity for c-kit and/or p63 may be useful in differentiating adenoid cystic carcinomas from other types of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / metabolism. Membrane Proteins / metabolism. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846389.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CKAP4 protein, human; 0 / Cadherins; 0 / Membrane Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


9. Marchiò C, Weigelt B, Reis-Filho JS: Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol; 2010 Mar;63(3):220-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas).
  • Adenoid cystic carcinoma (AdCC) is a tumour with myoepithelial differentiation and characterised by the presence of a dual population of basaloid and luminal cells arranged in specific growth patterns.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Salivary Gland Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20203221.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 113
  •  go-up   go-down


10. Serrano MF, El-Mofty SK, Gnepp DR, Lewis JS Jr: Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck. Hum Pathol; 2008 Apr;39(4):591-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of high molecular weight cytokeratins, but not p63, in the differential diagnosis of neuroendocrine and basaloid carcinomas of the head and neck.
  • High-grade neuroendocrine carcinomas of the head and neck overlap significantly in morphology with both basaloid squamous and solid-type adenoid cystic carcinomas.
  • High-grade neuroendocrine carcinomas have sheets of small cells with scant cytoplasm, granular chromatin, and inconspicuous nucleoli.
  • Basaloid squamous and adenoid cystic carcinomas are aggressive variants of their respective tumor types which both have nests of basaloid tumor cells with round nuclei, little cytoplasm, and inconspicuous nucleoli.
  • We performed high molecular weight cytokeratin (CK) and p63 immunohistochemistry on 19 neuroendocrine carcinomas, 18 basaloid squamous carcinomas, and 11 solid-type adenoid cystic carcinomas.
  • All basaloid squamous and adenoid cystic carcinomas were positive for CK 5/6 and 34betaE12.
  • Only 4 and 5 of the 19 neuroendocrine carcinomas, respectively, were positive for these markers.
  • Staining was focal in the neuroendocrine cases when positive, whereas almost all basaloid squamous and adenoid cystic carcinomas showed strong staining.
  • Almost all tumors of each type were positive for p63, including neuroendocrine carcinomas, but with different staining patterns.
  • Basaloid squamous carcinomas were diffusely positive, neuroendocrine carcinomas were diffusely positive, but with weak staining, and adenoid cystic carcinomas showed a distinct pattern with staining at the periphery of the cell nests only.
  • We conclude that high molecular weight cytokeratin immunostaining is helpful in distinguishing high-grade neuroendocrine carcinomas from similar tumor types.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basosquamous / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Head and Neck Neoplasms / diagnosis. Keratins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Keratin-5 / analysis. Keratin-6 / analysis. Male. Membrane Proteins / analysis. Middle Aged. Molecular Weight


11. Sørensen KB, Godballe C, de Stricker K, Krogdahl A: Parotid carcinoma: expression of kit protein and epidermal growth factor receptor. J Oral Pathol Med; 2006 May;35(5):286-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid carcinoma: expression of kit protein and epidermal growth factor receptor.
  • OBJECTIVES: Our aim is to investigate the expression of kit protein (KIT) and epidermal growth factor receptor (EGFR) in parotid carcinomas in order to correlate the expression to histology and prognosis.
  • Further we want to perform mutation analysis of KIT-positive adenoid cystic carcinomas.
  • PATIENTS AND METHODS: Formalin-fixed paraffin-embedded sections from 73 patients with parotid gland carcinomas were used for the study.
  • Twelve KIT-positive adenoid cystic carcinomas were examined for c-kit mutation in codon 816.
  • RESULTS: Of all carcinomas 25% were KIT-positive and 79% were EGFR-positive.
  • Ninety-two percentage of the adenoid cystic carcinomas were KIT-positive.
  • None of the adenoid cystic carcinomas had mutations in codon 816 of the c-kit gene.
  • Adenoid cystic carcinomas express KIT, but no mutations in codon 816 of the c-kit gene were identified.
  • [MeSH-major] Carcinoma, Adenoid Cystic / chemistry. Parotid Neoplasms / chemistry. Proto-Oncogene Proteins c-kit / analysis. Receptor, Epidermal Growth Factor / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16630292.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


12. Dong M, Ning Z, Newman MJ, Xu J, Dou G, Cao H, Shi Y, Gingras MA, Lu X, Feng F: Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. J Clin Oncol; 2009 May 20;27(15_suppl):3529

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.
  • 4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Falchook GS, Wheler JJ, Tannir NM, Naing A, Jackson E, Hong D, Lawhorn KN, Ng C, Amin H, Kurzrock R: Hypoxia-inducible factor-1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol; 2009 May 20;27(15_suppl):3555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two partial responses were observed in patients with renal cell carcinoma (RCC) (Total patients with RCC = 6).
  • Minor responses or stable disease lasting ≥4 months was achieved in 8 patients, including RCC (1), breast (1), leiomyosarcoma (1), nasopharyngeal (2), hepatocellular (1), neuroendocrine (1), lacrimal gland adenocystic carcinoma (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961363.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


1
Advertisement
4. Kasamatsu A, Endo Y, Uzawa K, Nakashima D, Koike H, Hashitani S, Numata T, Urade M, Tanzawa H: Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses. Int J Biochem Cell Biol; 2005 Sep;37(9):1869-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of candidate genes associated with salivary adenoid cystic carcinomas using combined comparative genomic hybridization and oligonucleotide microarray analyses.
  • Adenoid cystic carcinoma (ACC) of the salivary gland often has a variable clinical course with a poor prognosis.
  • The function with the highest P value was a cancer-related function (P = 2.52e-4 to 4.71e-2).
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Gene Expression Profiling. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908262.001).
  • [ISSN] 1357-2725
  • [Journal-full-title] The international journal of biochemistry & cell biology
  • [ISO-abbreviation] Int. J. Biochem. Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Neoplasm
  •  go-up   go-down


15. Le Péchoux C, Baldeyrou P, Ferreira I, Mahé M: [Thoracic adenoid cystic carcinomas]. Cancer Radiother; 2005 Nov;9(6-7):358-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracic adenoid cystic carcinomas].
  • Adenoid cystic carcinomas in the trachea are rare, but represent around 40% of all tracheal tumours.
  • Adenoid cystic carcinoma's growth rate is slow so that it is frequently diagnosed at an advanced stage.
  • Among inoperable patients treated with exclusive radiotherapy for tracheal tumours (including adenoid cystic but also squamous cell carcinomas of poorer prognosis), the recommended delivered dose should be over 60 Gy.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Carcinoma, Adenoid Cystic / surgery. Tracheal Neoplasms / radiotherapy. Tracheal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16168695.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 19
  •  go-up   go-down


16. Ye JH, Gao J, Wu YN, Hu YJ, Zhang CP, Xu TL: Identification of acid-sensing ion channels in adenoid cystic carcinomas. Biochem Biophys Res Commun; 2007 Apr 20;355(4):986-92
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of acid-sensing ion channels in adenoid cystic carcinomas.
  • The response of adenoid cystic carcinoma (ACC) cells to acidic solution was studied using whole-cell patch-clamp recording in the current study.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Membrane Proteins / metabolism. Nerve Tissue Proteins / metabolism. Sodium Channels / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17324378.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acid Sensing Ion Channels; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Protons; 0 / Sodium Channels; J41CSQ7QDS / Zinc
  •  go-up   go-down


17. Zvrko E, Golubović M: Laryngeal adenoid cystic carcinoma. Acta Otorhinolaryngol Ital; 2009 Oct;29(5):279-82
Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal adenoid cystic carcinoma.
  • Adenoid cystic carcinomas are malignant tumours and occur in the major and the minor salivary glands.
  • Laryngeal adenoid cystic carcinomas are rare and account for less than 1% of all malignant tumours in the larynx.
  • Adenoid cystic carcinoma is characterised by slow progression, multiple recurrences and late distant metastasis.
  • The aetiology of adenoid cystic carcinoma remains unknown.
  • In this article, the case of laryngeal adenoid cystic carcinoma is described in a 55-year-old male patient who presented with a 3-month history of prelaryngeal pain.
  • For patients with laryngeal adenoid cystic carcinomas, regular and long-term follow-up is mandatory, in order to detect relapses and metastases.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / surgery. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Laryngol Otol. 2001 May;115(5):388-92 [11410131.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 2003 Sep;120(4):244-8 [13130301.001]
  • [Cites] Cancer. 1973 Jan;31(1):117-29 [4345606.001]
  • [Cites] Cancer. 1977 Sep;40(3):1307-13 [198092.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Apr;99(4 Pt 1):277-80 [2158263.001]
  • [Cites] J Chin Med Assoc. 2006 Jul;69(7):322-5 [16903646.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 Jun-Jul;16(6):1375-7 [7677046.001]
  • [Cites] Otolaryngol Clin North Am. 1997 Apr;30(2):215-29 [9052666.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 May;108(5):485-9 [10335711.001]
  • [Cites] Sao Paulo Med J. 2006 Jan 5;124(1):26-30 [16612459.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Jul;132(7):767-70 [16847187.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1992 Dec;101(12):1024-6 [1463294.001]
  • (PMID = 20162031.001).
  • [ISSN] 1827-675X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2821129
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Laryngectomy / Larynx / Malignant tumours
  •  go-up   go-down


18. Romão RL, de Barros F, Maksoud Filho JG, Gonçalves ME, Cardoso S, Tannuri AC, Tannuri U: Malignant tumor of the trachea in children: diagnostic pitfalls and surgical management. J Pediatr Surg; 2009 Nov;44(11):e1-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, squamous cell and adenoid cystic carcinomas are the most common types of malignant primary tracheal tumors when all age groups are studied.
  • In the past 5 years, we treated 2 children with tracheal mucoepidermoid carcinoma.
  • Herein we report both cases and review the literature on the subject with particular emphasis on diagnosis and surgical management.
  • [MeSH-major] Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / surgery. Reconstructive Surgical Procedures / methods. Thoracotomy / methods. Tracheal Neoplasms / diagnosis. Tracheal Neoplasms / surgery
  • [MeSH-minor] Child. Child, Preschool. Disease-Free Survival. Humans. Prognosis. Retrospective Studies. Sternotomy / methods. Tomography, X-Ray Computed. Trachea / pathology. Trachea / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19944203.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Ito FA, Ito K, Coletta RD, Vargas PA, Lopes MA: Immunohistochemical study of androgen, estrogen and progesterone receptors in salivary gland tumors. Braz Oral Res; 2009 Oct-Dec;23(4):393-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this work was to study the immunohistochemical expression of androgen receptor, estrogen receptor and progesterone receptor in pleomorphic adenomas, Warthin's tumors, mucoepidermoid carcinomas and adenoid cystic carcinomas of salivary glands.
  • A total of 41 pleomorphic adenomas, 30 Warthin's tumors, 30 mucoepidermoid carcinomas and 30 adenoid cystic carcinomas were analyzed, and the immunohistochemical expression of these hormone receptors were assessed.
  • Androgen receptor was positive in 2 cases each of pleomorphic adenoma, mucoepidermoid carcinoma and adenoid cystic carcinoma.
  • In conclusion, the results do not support a role of estrogen and progesterone in the tumorigenesis of pleomorphic adenomas, Warthin's tumors, mucoepidermoid carcinomas and adenoid cystic carcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Complex and Mixed / pathology. Receptors, Androgen / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027446.001).
  • [ISSN] 1807-3107
  • [Journal-full-title] Brazilian oral research
  • [ISO-abbreviation] Braz Oral Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Receptors, Androgen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


20. Alves SM, Cardoso SV, de Fátima Bernardes V, Machado VC, Mesquita RA, Vieira do Carmo MA, Ferreira Aguiar MC: Metallothionein immunostaining in adenoid cystic carcinomas of the salivary glands. Oral Oncol; 2007 Mar;43(3):252-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metallothionein immunostaining in adenoid cystic carcinomas of the salivary glands.
  • Metallothionein (MT) is a protein that has been studied in several tumors as a prognostic factor and as a potential myoepithelial cell marker in breast cancer.
  • The aims of this study were to assess the immunohistochemical staining of MT in adenoid cystic carcinomas of the salivary glands (ACC), and to analyze possible morphological and quantitative variations among the solid, cribriform, and tubular histological subtypes.
  • [MeSH-major] Carcinoma, Adenoid Cystic / chemistry. Metallothionein / analysis. Neoplasm Proteins / analysis. Salivary Gland Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857408.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 9038-94-2 / Metallothionein
  •  go-up   go-down


26. Mithani SK, Shao C, Tan M, Smith IM, Califano JA, El-Naggar AK, Ha PK: Mitochondrial mutations in adenoid cystic carcinoma of the salivary glands. PLoS One; 2009 Dec 30;4(12):e8493
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial mutations in adenoid cystic carcinoma of the salivary glands.
  • No studies have investigated mitochondrial mutation in salivary gland adenoid cystic carcinomas.
  • METHODOLOGY: The entire mitochondrial genome of 22 salivary gland adenoid cystic carcinomas (ACC) of salivary glands and matched leukocyte DNA was sequenced to determine the frequency and distribution of mitochondrial mutations in ACC tumors.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 2006 Nov 18;243(2):193-201 [16412569.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):719-24 [15647368.001]
  • [Cites] Mol Cancer. 2006;5:73 [17166268.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):249-55 [17081685.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7540-5 [17456604.001]
  • [Cites] Cancer Genet Cytogenet. 2008 Feb;181(1):16-9 [18262047.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1655-63 [15753359.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3304-6 [15929189.001]
  • [Cites] Ann N Y Acad Sci. 2005 May;1042:109-22 [15965052.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):19-28 [15892105.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):8028-33 [16140977.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1099-103 [16142235.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jan;132(1):51-6 [16184379.001]
  • [Cites] DNA Repair (Amst). 2006 Feb 3;5(2):145-52 [15878696.001]
  • [Cites] Asian Pac J Cancer Prev. 2005 Oct-Dec;6(4):527-30 [16436005.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1880; author reply 1880-1 [16452251.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:93 [16620376.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5919-26 [16740732.001]
  • [Cites] Ann Hum Genet. 2006 Jul;70(Pt 4):488-95 [16759180.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):476-82 [16931588.001]
  • [Cites] Oral Oncol. 2006 Sep;42(8):759-69 [16757203.001]
  • [Cites] Science. 2008 May 2;320(5876):661-4 [18388260.001]
  • [Cites] Genome Res. 2009 Apr;19(4):576-80 [19211544.001]
  • [Cites] Science. 2000 Mar 17;287(5460):2017-9 [10720328.001]
  • [Cites] Oncogene. 2000 Apr 13;19(16):2060-6 [10803467.001]
  • [Cites] Cancer Lett. 2000 Jun 1;154(1):107-11 [10799746.001]
  • [Cites] Diabetes. 2000 Jul;49(7):1269-72 [10909988.001]
  • [Cites] Anticancer Res. 2000 May-Jun;20(3B):2169-75 [10928172.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):319-21 [11291064.001]
  • [Cites] Int J Cancer. 2001 Jun 20;96(3):149-58 [11410883.001]
  • [Cites] Genome Res. 2001 Nov;11(11):1913-25 [11691856.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):429-31 [11745425.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):972-6 [11861366.001]
  • [Cites] Head Neck. 2002 Jul;24(7):632-6 [12112535.001]
  • [Cites] Exp Physiol. 2003 Jan;88(1):41-56 [12525854.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Jun;37(2):186-94 [12696067.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):697-701 [12915881.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):71-8 [15013701.001]
  • [Cites] Genome Res. 2004 May;14(5):812-9 [15123581.001]
  • [Cites] Mol Cancer. 2004 Jul 12;3:19 [15248896.001]
  • [Cites] Genetics. 1992 Jan;130(1):163-73 [1732158.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1151-4 [8640776.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):495-8 [9374223.001]
  • [Cites] J Oral Maxillofac Surg. 1997 Dec;55(12):1460-9 [9393407.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):43-50 [9894453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7382-7 [10377423.001]
  • [Cites] Eur J Cancer. 1999 Feb;35(2):316-9 [10448277.001]
  • [Cites] Cancer. 1999 Sep 15;86(6):928-35 [10491517.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] Mod Pathol. 2004 Dec;17(12):1475-82 [15195113.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D823-8 [17178747.001]
  • (PMID = 20041111.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA118782; United States / NIDCR NIH HHS / DE / K08DE018463; United States / NIDCR NIH HHS / DE / R01 DE015939; United States / NIDCR NIH HHS / DE / 9P50DE019032; United States / NIDCR NIH HHS / DE / 1R01DE015939; United States / NCI NIH HHS / CA / 5P20CA118782; United States / NIDCR NIH HHS / DE / P50 DE019032; United States / NIDCR NIH HHS / DE / K08 DE018463
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amino Acids; 0 / DNA, Mitochondrial; 0U46U6E8UK / NAD
  • [Other-IDs] NLM/ PMC2795173
  •  go-up   go-down


27. Del Negro A, Ichihara E, Tincani AJ, Altemani A, Martins AS: Laryngeal adenoid cystic carcinoma: case report. Sao Paulo Med J; 2007 Sep 6;125(5):295-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal adenoid cystic carcinoma: case report.
  • CONTEXT: Adenoid cystic carcinomas are malignant tumors that occur in both the major and the minor salivary glands.
  • Adenoid cystic carcinomas account for less than 1% of all malignant tumors in the larynx, and only about 120 cases have been reported in the literature.
  • In this article, we describe a case of laryngeal adenoid cystic carcinoma and discuss its clinical characteristics and treatment.
  • CASE REPORT: We report on a case of laryngeal adenoid cystic carcinoma in a 55 year-old female patient who presented with dyspnea and hoarseness.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Laryngeal Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094899.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


28. Boukheris H, Curtis RE, Land CE, Dores GM: Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States. Cancer Epidemiol Biomarkers Prev; 2009 Nov;18(11):2899-906
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of carcinoma of the major salivary glands according to the WHO classification, 1992 to 2006: a population-based study in the United States.
  • BACKGROUND: Carcinomas of the major salivary glands (M-SGC) comprise a morphologically diverse group of rare tumors of largely unknown cause.
  • To gain insight into etiology, we evaluated incidence of M-SGC using the WHO classification schema (WHO-2005).
  • Squamous cell (IR, 3.44) and mucoepidermoid (IR, 3.23) carcinomas occurred most frequently among males, whereas mucoepidermoid (IR, 2.67), acinic cell (IR, 1.57), and adenoid cystic (IR, 1.40) carcinomas were most common among females.
  • Mucoepidermoid, acinic cell, and adenoid cystic carcinomas predominated in females through age approximately 50 years; thereafter, IRs of acinic cell and adenoid cystic carcinomas were nearly equal among females and males, whereas IRs of mucoepidermoid carcinoma among males exceeded IRs among females (IRR, 1.57; 95% CI, 1.38-1.78).
  • Except for mucoepidermoid and adenoid cystic carcinomas, which occurred equally among all races, other subtypes had significantly lower incidence among Blacks and Asians/Pacific Islanders than among Whites.
  • Adenoid cystic carcinoma occurred equally in the submandibular and parotid glands, and other M-SGC histologic subtypes evaluated had 77% to 98% lower IRs in the submandibular gland.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1095-100 [10613342.001]
  • [Cites] Community Dent Health. 2008 Sep;25(3):148-53 [18839720.001]
  • [Cites] Oral Oncol. 2002 Sep;38(6):610-7 [12167440.001]
  • [Cites] Oral Oncol. 2002 Oct;38(7):706-13 [12167424.001]
  • [Cites] Oral Dis. 2002 Sep;8(5):229-40 [12363107.001]
  • [Cites] Afr J Med Med Sci. 2001 Mar-Jun;30(1-2):95-8 [14510160.001]
  • [Cites] Cancer. 1971 Jun;27(6):1415-8 [4325986.001]
  • [Cites] Arch Otolaryngol. 1984 Jan;110(1):45-9 [6689907.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1854-9 [6478421.001]
  • [Cites] J Pathol. 1985 May;146(1):51-8 [4009321.001]
  • [Cites] Biometrics. 1985 Jun;41(2):361-72 [4027319.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Aust N Z J Surg. 1987 Jan;57(1):23-6 [3472508.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Oct;116(10):1163-6 [2206501.001]
  • [Cites] Int J Epidemiol. 1991 Sep;20(3):628-33 [1955246.001]
  • [Cites] J Clin Pathol. 1992 May;45(5):369-77 [1317882.001]
  • [Cites] East Afr Med J. 1992 Sep;69(9):525-30 [1286637.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):147-53 [8000993.001]
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Radiat Res. 1996 Jul;146(1):28-36 [8677295.001]
  • [Cites] Oral Oncol. 1997 May;33(3):169-76 [9307725.001]
  • [Cites] Otolaryngol Head Neck Surg. 1998 Feb;118(2):195-8 [9482552.001]
  • [Cites] Cancer Causes Control. 1999 Feb;10(1):27-33 [10334639.001]
  • [Cites] Epidemiology. 1999 Sep;10(5):528-30 [10468426.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Acta Otolaryngol. 2005 Feb;125(2):207-14 [15880955.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2137-50 [16682732.001]
  • [Cites] Head Neck. 2006 Jul;28(7):626-32 [16475198.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Dec;135(6):844-8 [17141071.001]
  • [Cites] Oral Oncol. 2008 Apr;44(4):407-17 [17825603.001]
  • [Cites] Cancer. 2008 May 1;112(9):1974-82 [18361448.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):768-70 [10622505.001]
  • (PMID = 19861510.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010183-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS144622; NLM/ PMC2779732
  •  go-up   go-down


29. Giannini PJ, Shetty KV, Horan SL, Reid WD, Litchmore LL: Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature. Oral Oncol; 2006 Nov;42(10):1029-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the buccal vestibule: A case report and review of the literature.
  • Adenoid cystic carcinoma is the fifth most common salivary gland malignancy following mucoepidermoid carcinoma, adenocarcinoma not otherwise specified (NOS), acinic cell adenocarcinoma and polymorphous low-grade adenocarcinoma (PLGA).
  • Greater than half of adenoid cystic carcinomas occur in the parotid and submandibular glands.
  • Adenoid cystic carcinoma tends to have a protracted clinical course with wide infiltration and late distant metastases.
  • We present a case of an adenoid cystic carcinoma of the buccal vestibule in a 59-year-old Caucasian female patient that she had been aware of for 15 years.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Mouth Neoplasms / pathology. Salivary Gland Neoplasms / pathology


30. Kim B: Palliative radiotherapy in a patient with pulmonary adenoid cystic carcinoma. Cancer Res Treat; 2007 Dec;39(4):185-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Palliative radiotherapy in a patient with pulmonary adenoid cystic carcinoma.
  • Primary adenoid cystic carcinoma in the lung is very rare, so its clinicopathologic characteristics have usually been extrapolated from the salivary disease.
  • However, the clinical courses of pulmonary adenoid cystic carcinomas may be different from those of salivary disease, and individual differences may also exist.
  • I report here on a case of a patient who was initially diagnosed as pulmonary adenoid cystic carcinoma with liver metastases and the tumor showed extreme radiosensitivity, but it also underwent an aggressive clinical course.
  • Adenoid cystic carcinoma is usually known to be a slowly growing tumor, but it may rapidly disseminate, like in this patient.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Apr 15;67(8):2159-64 [1706215.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] J Thorac Cardiovasc Surg. 1988 Aug;96(2):271-7 [2456426.001]
  • [Cites] Hum Pathol. 1982 Oct;13(10):916-24 [6290368.001]
  • [Cites] Radiol Clin North Am. 1978 Aug;16(2):227-46 [212775.001]
  • [Cites] Chest. 2004 Mar;125(3):1160-5 [15006985.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1390-7 [7509254.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Oct;22(4):621-5 [12297183.001]
  • [Cites] Head Neck. 2002 Aug;24(8):779-83 [12203804.001]
  • [Cites] Ann Thorac Cardiovasc Surg. 2002 Apr;8(2):74-7 [12027791.001]
  • [Cites] Am J Surg Pathol. 2002 Apr;26(4):413-20 [11914618.001]
  • [Cites] Ann Thorac Surg. 2004 Dec;78(6):1889-96; discussion 1896-7 [15560996.001]
  • [Cites] Mod Pathol. 1996 Mar;9(3):215-9 [8685217.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1193-7 [14623749.001]
  • (PMID = 19746187.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739373
  • [Keywords] NOTNLM ; Prognostic factor / Pulmonary adenoid cystic carcinoma / Radiosensitivity
  •  go-up   go-down


31. Unsal A, Karaman CZ, Kacar F, Sen S: [Atypically located pulmonary adenoid cystic carcinoma: case report]. Tuberk Toraks; 2008;56(2):210-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Atypically located pulmonary adenoid cystic carcinoma: case report].
  • [Transliterated title] Atipik yerleşimli pulmoner adenoid kistik karsinom: Olgu sunumu.
  • Pulmonary adenoid cystic carcinomas typically arise from central extra-pulmonary airways and lung involvement is rare.
  • On the other hand, this entity should be kept in mind because it has a more favorable clinical course compared to the primary lung adenocarcinoma.
  • In this paper; the clinical, radiological and pathological aspects of a 47 years old man with a complaint of chronic cough, who was found to have a mass lesion at upper lobe of right lung and a final diagnosis of primary pulmonary adenoid cystic carcinoma according to transbronchial needle biopsy and pneumonectomy, was presented.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Lung Neoplasms / pathology. Pneumonectomy / methods
  • [MeSH-minor] Biopsy, Fine-Needle / methods. Bronchoscopy / methods. Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18701983.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


32. Fehr A, Stenman G, Bullerdiek J, Löning T: [Molecular markers in salivary gland tumors: their use in diagnostic and prognostic workup]. Pathologe; 2009 Nov;30(6):466-71
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CRTC1-MAML2 in mucoepidermoid carcinoma, or PLAG1 and HMGA2 in pleomorphic adenoma.
  • This is also true for the most frequent malignant salivary gland tumors after the mucoepidermoid carcinoma, i.e. adenoid cystic carcinomas and acinic cell carcinomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Neoplasm Proteins / genetics. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adenoma, Pleomorphic / diagnosis. Adenoma, Pleomorphic / genetics. Adenoma, Pleomorphic / pathology. Carcinoma, Acinar Cell. Carcinoma, Adenoid Cystic. Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / pathology. Chromosome Aberrations. Comparative Genomic Hybridization. DNA Mutational Analysis. DNA-Binding Proteins. Gene Fusion. HMGA2 Protein. Humans. Nuclear Proteins. Prognosis. Protein Array Analysis. Salivary Glands / pathology. Transcription Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19784654.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CRTC1 protein, human; 0 / DNA-Binding Proteins; 0 / HMGA2 Protein; 0 / MAML2 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / PLAG1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


33. Furuse C, Cury PR, de Araújo NS, de Araújo VC: Application of two different clones of vimentin to the diagnosis of salivary gland tumors. Appl Immunohistochem Mol Morphol; 2006 Jun;14(2):217-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of two different clones of vimentin to the diagnosis of salivary gland tumors.
  • This study was undertaken to show these differences comparing the immunoexpression of two clones of vimentin (V9 and Vim 3B4, DAKO, Carpenteria, CA) using 10 pleomorphic adenomas, 10 adenoid cystic carcinomas, and 4 epithelial/myoepithelial carcinomas of the salivary glands.
  • The Vim 3B4 clone was capable of detecting some myoepithelial cells, the plasmacytoid or modified myoepithelial cells in the pleomorphic adenoma, but was very weak in epithelial/-myoepithelial carcinomas.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785793.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Vimentin
  •  go-up   go-down


34. Lee JH, Lee JH, Kim A, Kim I, Chae YS: Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas. Pathol Int; 2005 Jul;55(7):386-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas.
  • The differential diagnosis of salivary gland carcinoma is often difficult because of the confusing histopathological features of the different types of salivary gland carcinomas.
  • The expression of MUC3, MUC5AC, MUC6, cytokeratin (CK)7 and CK20 was studied in 20 mucoepidermoid carcinomas (MEC), 20 adenoid cystic carcinomas (AdCC), and 11 acinic cell carcinomas (ACC).
  • These findings will be very useful for the differential diagnosis of the salivary gland carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / biosynthesis. Keratin-20. Keratin-7. Keratins / biosynthesis. Male. Middle Aged. Mucin 5AC. Mucin-3. Mucins / biosynthesis

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15982212.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-3; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


35. Schulz-Ertner D, Nikoghosyan A, Didinger B, Münter M, Jäkel O, Karger CP, Debus J: Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer; 2005 Jul 15;104(2):338-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques.
  • BACKGROUND: The authors evaluated whether modern photon techniques, such as stereotactic fractionated radiation therapy (FSRT) or intensity-modulated RT, outweighed the biologic advantages of high-linear-energy transfer RT in the treatment of patients with locally advanced adenoid cystic carcinomas (ACC) that infiltrated the skull base or the orbit.
  • Disease-free and overall survival rates at 2 years/4 years were 71.5%/53% and 86.6%/75.8% for Group A and 69.2%/23% and 77.9%/77.9% for Group B, respectively.
  • [MeSH-major] Carbon Radioisotopes / therapeutic use. Carcinoma, Adenoid Cystic / radiotherapy. Photons / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15937907.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes
  •  go-up   go-down


36. Seethala RR: An update on grading of salivary gland carcinomas. Head Neck Pathol; 2009 Mar;3(1):69-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An update on grading of salivary gland carcinomas.
  • Histologic grade is a significant predictor of outcome in salivary gland carcinomas.
  • However, the sheer variety of tumor type and the rarity of these tumors pose challenges to devising highly predictive grading schemes.
  • As our knowledge base has evolved, it is clear that carcinoma ex pleomorphic adenoma is not automatically a high grade tumor as is traditionally suggested.
  • These tumors should be further qualified as to type/grade of carcinoma and extent, since intracapsular and minimally invasive carcinomas ex pleomorphic adenoma behave favorably.
  • The two carcinoma types for which grading schemes are common include adenoid cystic carcinoma and mucoepidermoid carcinoma.
  • Adenoid cystic carcinomas are graded based solely on pattern with solid components portending a worse prognosis.
  • Occasionally, adenoid cystic carcinomas may undergo transformation to pleomorphic high grade carcinomas.
  • Mucoepidermoid carcinomas are graded in a three tier fashion based on a constellation of features including cystic component, border, mitoses, anaplasia, and perineural invasion among others.
  • [MeSH-major] Adenocarcinoma / pathology. Salivary Gland Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Nov;133(5):702-8 [16274796.001]
  • [Cites] Cancer. 2008 Oct 15;113(8):2082-9 [18720358.001]
  • [Cites] Am J Surg Pathol. 2009 Mar;33(3):409-16 [18971778.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • [Cites] Acta Otolaryngol. 2002 Oct;122(7):758-64 [12484654.001]
  • [Cites] Cancer. 1978 Jul;42(1):265-82 [208752.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Oct;99(10 Pt 1):835-8 [2221741.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):172-9 [1985714.001]
  • [Cites] Am J Surg. 1992 Dec;164(6):623-8 [1334380.001]
  • [Cites] Hum Pathol. 1997 May;28(5):595-600 [9158708.001]
  • [Cites] APMIS. 1997 Jul;105(7):559-65 [9269302.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1217-24 [9529011.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Feb;125(2):149-52 [10037280.001]
  • [Cites] Cancer. 1953 Nov;6(6):1065-133 [13106826.001]
  • [Cites] Br J Surg. 1958 Mar 18;45(193):477-87 [13536351.001]
  • [Cites] J Oral Maxillofac Surg. 2005 Jul;63(7):917-28 [16003616.001]
  • [Cites] Laryngoscope. 2008 Feb;118(2):258-62 [18030166.001]
  • (PMID = 20596994.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  • [Other-IDs] NLM/ PMC2807532
  • [Keywords] NOTNLM ; Adenoid cystic carcinoma / Carcinoma ex pleomorphic adenoma / Grading / High grade transformation / Mucoepidermoid carcinoma / Salivary carcinoma
  •  go-up   go-down


37. Dequanter D, Andry G, Lothaire P, Larsimont D, Deraemaecker R: Wide localized excision and reconstruction for minor salivary gland tumours. B-ENT; 2005;1(4):187-90
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Four consecutive patients suffering from minor salivary gland tumours of the upper aerodigestive tract were treated: two had adenoid cystic carcinomas (one of the lateral oropharyngeal mucosa, one of the retromolar area); one had a polymorphous low-grade carcinoma (at the base of the tongue); and one had mucoepidermoid carcinoma (on the floor of the mouth).
  • Two patients, locally controlled, with adenoid cystic carcinomas died: one from brain metastases (four years post-surgery), the other with pulmonary metastases (eight-years post-surgery).
  • One patient is alive with a recurrent tumour of the pterygomaxillary fossa (without trismus) sixteen years after the original operation; another patient is free of recurrent disease at the base of the tongue but has recently undergone surgery, with success, for two pulmonary metastases sixty months after the initial surgery.
  • CONCLUSIONS: For minor salivary gland carcinoma of the head and neck, large resection with immediate reconstruction affords fast recovery and long-lasting locoregional control.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Carcinoma, Mucoepidermoid / surgery. Neck Dissection / methods. Reconstructive Surgical Procedures / methods. Salivary Gland Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16429751.001).
  • [ISSN] 1781-782X
  • [Journal-full-title] B-ENT
  • [ISO-abbreviation] B-ENT
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


38. Huang ZQ, Chen WL, Li HG, Li JS, Xu ZY, Lin ZY: Extracellular matrix metalloproteinase inducer expression in salivary gland tumors: a correlation with microvessel density. J Craniofac Surg; 2010 Nov;21(6):1855-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracellular matrix metalloproteinase inducer expression in mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher than in normal salivary gland tissues and pleomorphic adenomas (P < 0.05).
  • The MVD of mucoepidermoid carcinomas and adenoid cystic carcinomas was significantly higher compared with pleomorphic adenomas (P < 0.05).
  • [MeSH-minor] Adenoma, Pleomorphic / blood supply. Adenoma, Pleomorphic / immunology. Angiogenesis Inducing Agents / analysis. Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / blood supply. Carcinoma, Adenoid Cystic / immunology. Carcinoma, Mucoepidermoid / blood supply. Carcinoma, Mucoepidermoid / immunology. Epithelium / blood supply. Epithelium / immunology. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Salivary Ducts / blood supply. Salivary Ducts / immunology. Salivary Glands / blood supply. Salivary Glands / immunology

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119439.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antigens, CD34; 0 / Antigens, Neoplasm; 0 / BSG protein, human; 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 136894-56-9 / Antigens, CD147
  •  go-up   go-down


39. Neves Cde O, Soares AB, Costa AF, de Araujo VC, Furuse C, Juliano PB, Altemani A: CD10 (Neutral Endopeptidase) Expression in Myoepithelial Cells of Salivary Neoplasms. Appl Immunohistochem Mol Morphol; 2010 Mar;18(2):172-8
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In salivary glands, expression of CD10 has only been used to identify neoplastic myoepithelial cells of pleomorphic adenomas and myoepithelial carcinomas.
  • When the different groups of tumors were compared, epithelial-myoepithelial carcinomas (EMEC) showed a stark contrast with the others (83.3% of cases with CD10 expression).
  • Surprisingly, adenoid cystic carcinomas and basal cell adenomas were negative in 100% of the cases.
  • Myoepitheliomas, pleomorphic adenomas, and myoepithelial carcinomas were positive in 27.7%, 30.0%, and 40% of the cases, respectively.
  • However, the gain of this protein is not a sensitive marker for detecting myoepithelial cells in the majority of the tumors, except for EMEC.
  • The high expression of CD10 by this carcinoma can be a valuable tool to separate EMEC from the tubular variant of adenoid cystic carcinomas in small incisional biopsies, where the precise diagnosis may be impossible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19752720.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ACTA2 protein, human; 0 / Actins; 0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


40. Shigeishi H, Ohta K, Hiraoka M, Fujimoto S, Minami M, Higashikawa K, Kamata N: Expression of TPX2 in salivary gland carcinomas. Oncol Rep; 2009 Feb;21(2):341-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TPX2 in salivary gland carcinomas.
  • The purpose of this study was to clarify the expression of TPX2 mRNA and correlation between TPX2 and clinicopathological factors in salivary gland carcinomas.
  • The expression of TPX2 mRNA was investigated in 20 human salivary gland carcinomas (8 mucoepidermoid carcinomas, 7 adenoid cystic carcinomas, 5 acinic cell carcinomas) and 6 normal submandibular glands using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR).
  • The mean expression level of TPX2 mRNA was higher in mucoepidermoid carcinomas (0.53+/-0.51) than in normal submandibular glands (0.047+/-0.029); a significant association was found (Mann-Whitney U test, P=0.0067).
  • The mean expression levels of TPX2 were also higher in acinic cell carcinomas (0.45+/-0.49) and adenoid cystic carcinomas (0.28+/-0.22) than in normal submandibular glands.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / metabolism. Cell Cycle Proteins / biosynthesis. Microtubule-Associated Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148505.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Extracellular Matrix Proteins; 0 / Microtubule-Associated Proteins; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / TPX2 protein, human; 0 / hyaluronan-mediated motility receptor
  •  go-up   go-down


41. Affolter A, Helmbrecht S, Finger S, Hörmann K, Götte K: Altered expression of cell cycle regulators p21, p27, and p53 in tumors of salivary glands and paranasal sinuses. Oncol Rep; 2005 Jun;13(6):1089-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine adenoid cystic carcinomas, 5 adenocarcinomas, 4 cylindrical cell carcinomas, as well as 30 pleomorphic adenomas and 26 inverted papillomas, were studied.
  • In 78% of all adenoid cystic carcinomas a complete loss of p27 expression could be identified, whereas 60% of the adenocarcinomas overexpressed the protein.
  • The majority of cylindrical cell carcinomas showed distinct cytoplasmic accumulation of p27.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Adenoid Cystic / metabolism. Cell Cycle Proteins / metabolism. Paranasal Sinus Neoplasms / metabolism. Paranasal Sinuses / metabolism. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15870926.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


42. Götte K, Ganssmann S, Affolter A, Schäfer C, Riedel F, Arens N, Finger S, Hörmann K: Dual FISH analysis of benign and malignant tumors of the salivary glands and paranasal sinuses. Oncol Rep; 2005 Nov;14(5):1103-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined 58 of these tumors (14 adenoid cystic carcinomas, 9 adenocarcinomas, 5 cylindrical carcinomas, 11 pleomorphic adenomas, and 19 inverted papillomas) by dual fluorescence in situ hybridization (FISH) with centromere-specific probes on six chromosomes (3, 7, 9, 11, 17, and 18) for numerical changes.
  • In adenoid cystic carcinomas, monosomy of chromosome 17 and polysomy of chromosomes 3, 9 and 11 were most frequently encountered.
  • In cylindrical cell carcinomas, polysomy of chromosomes 7, 9, 11 and 17 was present in the majority of tumors.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenoma / diagnosis. Adenoma / genetics. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Adenoid Cystic / genetics. Chromosome Aberrations. Papilloma / diagnosis. Papilloma / genetics. Salivary Gland Neoplasms / diagnosis. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Diagnosis, Differential. Humans. In Situ Hybridization, Fluorescence. Salivary Gland Diseases / diagnosis. Salivary Gland Diseases / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211271.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


43. Crisi GM, Marconi SA, Makari-Judson G, Goulart RA: Expression of c-kit in adenoid cystic carcinoma of the breast. Am J Clin Pathol; 2005 Nov;124(5):733-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in adenoid cystic carcinoma of the breast.
  • Breast adenoid cystic carcinoma (BACC) is a biologically distinct tumor with morphologic mimickers, which might make accurate classification problematic.
  • Because c-kit expression has been reported in adenoid cystic carcinoma of various anatomic sites, we evaluated BACC for c-kit by immunohistochemical analysis, comparing the findings to similarly stained mimickers.
  • Tested cases included 6 BACCs, 15 low-grade infiltrating ductal carcinomas (LGIDCs) chosen as potential mimickers, and 15 head-neck adenoid cystic carcinomas (HNACCs).
  • Immunohistochemical evaluation for c-kit might aid in accurately classifying carcinomas with histologic features overlapping adenoid cystic carcinoma and LGIDC.
  • [MeSH-major] Breast Neoplasms / chemistry. Carcinoma, Adenoid Cystic / chemistry. Proto-Oncogene Proteins c-kit / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / chemistry. Carcinoma, Ductal, Breast / pathology. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203286.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


44. Seethala RR, Pasha TL, Raghunath PN, Livolsi VA, Zhang PJ: The selective expression of CD43 in adenoid cystic carcinoma. Appl Immunohistochem Mol Morphol; 2008 Mar;16(2):165-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The selective expression of CD43 in adenoid cystic carcinoma.
  • We describe CD43 expression by immunohistochemistry and mRNA in situ hybridization in adenoid cystic carcinomas (ACCs).
  • CD43 immunoreactivity with 2 different antibodies was detected mainly in ACC but also 1 membranous type basal cell adenocarcinoma and 1 colonic adenocarcinoma.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18227725.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD43; 0 / RNA, Messenger; 0 / UN1 sialoglycoprotein, human
  •  go-up   go-down


45. Qi ZZ, Shang DH, Qu CF, Sun CF: [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma]. Shanghai Kou Qiang Yi Xue; 2007 Jun;16(3):243-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of M-phase promoting factor in salivary adenoid cystic carcinoma].
  • PURPOSE: To study the expression and clinical significance of M-phase promoting factor (MPF) in salivary adenoid cystic carcinoma (SACC).
  • METHODS: The expression of MPF was investigated in 40 salivary adenoid cystic carcinomas and 40 normal salivary tissues by immunohistochemistry.
  • RESULTS: The expression of MPF was significantly higher in salivary adenoid cystic carcinoma than in normal salivary tissues(P<0.05).
  • There was significant correlation between the level of MPF expression and pathological type(P<0.05).
  • CONCLUSIONS: MPF highly expressed in salivary adenoid cystic carcinoma, salivary adenoid cystic carcinoma correlated with the expression of MPF and the abnormal activation of MPF was one of the factors for the proliferation of salivary adenoid cystic carcinoma.
  • Metastasis in salivary adenoid cystic carcinoma correlated with the expression of MPF.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Maturation-Promoting Factor / metabolism. Salivary Gland Neoplasms / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660907.001).
  • [ISSN] 1006-7248
  • [Journal-full-title] Shanghai kou qiang yi xue = Shanghai journal of stomatology
  • [ISO-abbreviation] Shanghai Kou Qiang Yi Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.11.22 / Maturation-Promoting Factor
  •  go-up   go-down


46. Vranic S, Frkovic-Grazio S, Lamovec J, Serdarevic F, Gurjeva O, Palazzo J, Bilalovic N, Lee LM, Gatalica Z: Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification. Hum Pathol; 2010 Nov;41(11):1617-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
  • Adenoid cystic carcinoma of the breast is a rare subtype of breast cancer with basal-like features.
  • Published studies on breast adenoid cystic carcinoma are limited, resulting in relatively scarce information on the value of predictive tumor markers.
  • We studied 20 primary cases of adenoid cystic carcinoma of the breast for expression of estrogen receptor, progesterone receptor, androgen receptor, epidermal growth factor receptor, HER-2/neu, and topoisomerase IIα using immunohistochemistry and fluorescent in situ hybridization methods.
  • Our study shows that the majority of adenoid cystic carcinomas of the breast do not overexpress Her-2/neu, topoisomerase IIα, or estrogen receptor, and thus, they are unlikely to respond to therapies targeting these proteins.
  • However, these tumors frequently over-express epidermal growth factor receptor, indicating a potential benefit from anti-epidermal growth factor receptor therapy for patients with advanced adenoid cystic carcinomas of the breast.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Breast Neoplasms, Male / metabolism. Carcinoma, Adenoid Cystic / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Gene Amplification. Gene Expression Regulation, Neoplastic. Receptor, Epidermal Growth Factor / genetics

  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20688355.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


47. de Lima Mde D, Marques YM, Alves Sde M Jr, Freitas VM, Soares FA, de Araújo VC, Pinto Ddos S Jr, Mantesso A: MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma. Cancer Epidemiol; 2009 Aug;33(2):142-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2, P53, P21WAF1 and pAKT protein levels in genesis and behaviour of adenoid cystic carcinoma.
  • The aim of this study was to evaluate and to correlate MDM2, P53, P21(WAF1) and pAKT protein expressions in adenoid cystic carcinomas (ACC).
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins c-mdm2 / metabolism. Salivary Gland Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679062.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


48. Epivatianos A, Poulopoulos A, Dimitrakopoulos I, Andreadis D, Nomikos A, Vlahou S, Papazoglou G, Barbatis C: Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Oral Oncol; 2007 Jan;43(1):67-76
Genetic Alliance. consumer health - Polymorphous low-grade adenocarcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Application of alpha-smooth muscle actin and c-kit in the differential diagnosis of adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma.
  • The expression of vimentin, alpha-smooth muscle actin (alpha-SMA) and c-kit in adenoid cystic carcinomas (AdCCs) and polymorphous low-grade adenocarcinomas (PLGAs) was investigated immunohistochemically to evaluate the application of these markers to distinguish AdCCs from PLGAs when the histological features are equivocal.
  • The immunoreactivity of c-kit in all positive cases of AdCCs (83%) and PLGAs (41%) was more than 50% and less than 50% of tumor cells respectively.
  • The results of this study support the potential application of alpha-SMA and c-kit as an adjunctive aid in the differential diagnosis of AdCCs from PLGAs.
  • [MeSH-major] Actins / analysis. Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Carcinoma, Adenoid Cystic / diagnosis. Proto-Oncogene Proteins c-kit / analysis. Vimentin / analysis
  • [MeSH-minor] Cytoskeletal Proteins. Diagnosis, Differential. Humans. Immunohistochemistry. Muscle Proteins. Retrospective Studies

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16807072.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Muscle Proteins; 0 / Smooth muscle protein, human; 0 / Vimentin; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


49. Zhou CX, Gao Y: [Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance]. Zhonghua Kou Qiang Yi Xue Za Zhi; 2006 Oct;41(10):623-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinoma and its significance].
  • OBJECTIVE: To investigate the expression of Pin1, beta-catenin and cyclin D1 in salivary adenoid cystic carcinomas (SACC) and to evaluate the role of beta-catenin and Pin1 in SACC carcinogenesis.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Peptidylprolyl Isomerase / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Gland Neoplasms / pathology. beta Catenin / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17129455.001).
  • [ISSN] 1002-0098
  • [Journal-full-title] Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology
  • [ISO-abbreviation] Zhonghua Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / CTNNB1 protein, human; 0 / NIMA-interacting peptidylprolyl isomerase; 0 / beta Catenin; 136601-57-5 / Cyclin D1; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


50. Huang SY, Zhang DS, Han JQ, Zhang N, Zhang SZ, Mu WL, Wei FC: Radiosensitization and anti-tumour effects of cytosine deaminase and thymidine kinase fusion suicide gene in human adenoid cystic carcinoma cells. J Int Med Res; 2009 Mar-Apr;37(2):479-90
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiosensitization and anti-tumour effects of cytosine deaminase and thymidine kinase fusion suicide gene in human adenoid cystic carcinoma cells.
  • Herpes simplex virus thymidine kinase (HSV-TK) and Escherichia coli cytosine deaminase (CD) can convert innocuous prodrugs into cytotoxic metabolites and are being investigated for use in gene therapy for cancer.
  • Human adenoid cystic carcinoma (ACC-2) cells transduced with a CD/HSV-TK fusion gene (ACC-2/CD-TK cells) were found to be more sensitive to radiation than ACC-2 cells when exposed to 5-fluorocytosine (5-FC; 40 microg/ml) plus ganciclovir (0.1 microg/ml) for 48 h before irradiation.
  • This study, therefore, indicates that addition of radiation might substantially improve the therapeutic potential of CD-TK fusion gene therapy of human adenoid cystic carcinomas.
  • [MeSH-major] Artificial Gene Fusion. Carcinoma, Adenoid Cystic / pathology. Cytosine Deaminase / metabolism. Genes, Transgenic, Suicide. Radiation Tolerance. Thymidine Kinase / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • Hazardous Substances Data Bank. FLUCYTOSINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383243.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; D83282DT06 / Flucytosine; EC 2.7.1.21 / Thymidine Kinase; EC 3.5.4.1 / Cytosine Deaminase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


51. Furuse C, Sousa SO, Nunes FD, Magalhães MH, Araújo VC: Myoepithelial cell markers in salivary gland neoplasms. Int J Surg Pathol; 2005 Jan;13(1):57-65
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared the immunoexpression of 5 myoepithelial cell (MEC) markers (alpha-smooth-muscle actin, calponin, h-caldesmon, vimentin, and S-100-protein) using 16 pleomorphic adenomas (PA), 15 adenoid cystic carcinomas (ACC), and 3 epithelial-myoepithelial carcinomas (EMC) of salivary glands.
  • Calponin was similar to alpha-smooth-muscle actin, except for polygonal and plasmacytoid cells of PA and for solid ACC, which showed alpha-smooth-muscle actin negative and calponin positive.
  • [MeSH-major] Adenoma, Pleomorphic / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15735856.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / S100 Proteins; 0 / Vimentin; 0 / calponin
  •  go-up   go-down


52. Lewandowski L, Osmola K, Nowaczyk M: [Malignant tumors of the oral cavity and neck in clinic of maxillo-facial surgery in Poznań from 2002-2004]. Otolaryngol Pol; 2007;61(3):286-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic studies have revealed a increased number of squamous cell carcinomas and other malignant tumors as lymphomas, adenoid cystic carcinomas and sarcomas of the oro-facial region.
  • [MeSH-major] Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / secondary. Lymphoma / surgery. Mouth Neoplasms / surgery. Sarcoma / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17847782.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


53. de Araújo VC, Furuse C, Cury PR, Altemani A, de Araújo NS: STAT3 expression in salivary gland tumours. Oral Oncol; 2008 May;44(5):439-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty biopsies of salivary gland tumours (9 pleomorphic adenomas, 12 adenoid cystic carcinomas, 7 epithelial-myoepithelial carcinomas, 10 polymorphous low-grade adenocarcinomas and 12 mucoepidermoid carcinomas) and 10 normal salivary glands were immunohistochemically labeled for STAT3 and Phospho-STAT3 (STAT3P).
  • The results showed that, in normal salivary gland, STAT3 was expressed in cytoplasm and STAT3P in nuclei of all tissue cells, except in large mucous acinar cells for which both antibodies were negative.
  • In pleomorphic adenoma, the expression was the same as in normal glands.
  • The most important one was the presence of STAT3 in the nuclei of the malignant tumour cells, most evident in the cribriform-type of adenoid cystic carcinoma.
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Female. Humans. Immunohistochemistry. Male

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826306.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


54. Tiltman AJ: The pathology of cervical tumours. Best Pract Res Clin Obstet Gynaecol; 2005 Aug;19(4):485-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas of the cervix may be categorized on morphological grounds into four main groups: squamous carcinomas; adenocarcinomas; neuro-endocrine tumours; and others including adenosquamous carcinomas.
  • Invasive squamous carcinomas and adenocarcinomas are preceded by cervical intra-epithelial neoplasia and cervical glandular intra-epithelial neoplasia, respectively.
  • Micro-invasive carcinomas with stromal invasion less than 3mm in depth have a minimal chance of lymph node metastasis.
  • Small cell carcinomas, large cell neuro-endocrine carcinomas and possibly adenoid cystic carcinomas are aggressive.
  • With these exceptions, it is doubtful whether tumour type is of much clinical significance.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150389.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 94
  •  go-up   go-down


55. Furuse C, Cury PR, Altemani A, dos Santos Pinto D Jr, de Araújo NS, de Araújo VC: Beta-catenin and E-cadherin expression in salivary gland tumors. Int J Surg Pathol; 2006 Jul;14(3):212-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twelve biopsy specimens from cases diagnosed as pleomorphic adenoma, 17 adenoid cystic carcinomas, 10 epithelial-myoepithelial carcinomas, and 4 polymorphous low-grade adenocarcinomas were immunohistochemically labeled for E-cadherin and beta-catenin antibodies.
  • In the epithelial-myoepithelial carcinomas, myoepithelial cells exhibited diffuse nuclear staining, although occasional cells presented only focal labeling.
  • Epithelial-myoepithelial carcinomas present changes in [.beta]-catenin expression but the other salivary tumors studied do not, which may reflect divergence in tumorigenesis of this extensive subset of salivary gland tumors.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Cadherins / metabolism. Carcinoma, Adenoid Cystic / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Surg Pathol. 2007 Apr;15(2):219-20 [17478787.001]
  • (PMID = 16959701.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / beta Catenin
  •  go-up   go-down


56. Gil Z, Orr-Urtreger A, Voskoboinik N, Trejo-Leider L, Shomrat R, Fliss DM: Cytogenetic analysis of 101 skull base tumors. Head Neck; 2008 May;30(5):567-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recurrent chromosomal breakpoints were identified in squamous cell carcinomas, adenoid cystic carcinomas (ACCs), sinonasal undifferentiated carcinomas, chordomas, and sarcomas.
  • Specific breakpoints established the diagnosis of various soft tissue sarcomas.
  • CONCLUSION: This study highlights the value of cytogenetic analysis for diagnosis of skull base tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18098307.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Sakamoto K, Ono T, Nakamura Y, Harada H, Nakashima T: Expression of cluster of differentiation 9 glycoprotein in benign and malignant parotid gland tumours. J Laryngol Otol Suppl; 2009;(31):58-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regarding benign parotid gland tumours, cluster of differentiation 9 glycoprotein was present in 13 of 18 pleomorphic adenomas, in all Warthin tumours tested (21/21) and in all cases of basal cell adenoma tested (four of four).
  • Cluster of differentiation 9 glycoprotein was present in 11 of 14 mucoepidermoid carcinomas, in two of five acinic cell carcinomas and in two of five adenoid cystic carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19460206.001).
  • [ISSN] 0144-2945
  • [Journal-full-title] The Journal of laryngology and otology. Supplement
  • [ISO-abbreviation] J Laryngol Otol Suppl
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD9; 0 / CD9 protein, human; 0 / Membrane Glycoproteins; 0 / Neoplasm Proteins
  •  go-up   go-down


58. Sygut D, Bień S, Ziółkowska M, Sporny S: Immunohistochemical expression of androgen receptor in salivary gland cancers. Pol J Pathol; 2008;59(4):205-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accidental discovery of androgen receptor (AR) expression in high-grade salivary gland cancer led to evaluation of that finding.
  • Nuclear immunoreactivity for AR was demonstrated in 3 of 4 salivary duct carcinomas, 2 of 7 adenocarcinomas NOS and 1 of 2 carcinoma ex pleomorphic adenoma for both antibodies.
  • There was no immunoreactivity seen in 13 adenoid cystic carcinomas, 7 mucoepidermoid carcinomas and 4 acinic cell carcinomas.
  • [MeSH-major] Carcinoma / metabolism. Receptors, Androgen / biosynthesis. Salivary Gland Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391487.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


59. Shigeishi H, Mizuta K, Higashikawa K, Yoneda S, Ono S, Kamata N: Correlation of CENP-F gene expression with tumor-proliferating activity in human salivary gland tumors. Oral Oncol; 2005 Aug;41(7):716-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the expression of Centromere protein F (CENP-F) mRNA in 26 human salivary gland tumors (seven pleomorphic adenomas, three Warthin tumors, seven mucoepidermoid carcinomas, four adenoid cystic carcinomas, four acinic cell carcinomas and one malignant myoepithelioma) and four normal submandibular glands using the real time quantitative reverse transcription-polymerase chain reaction (RT-PCR).
  • [MeSH-major] Adenoma / genetics. Chromosomal Proteins, Non-Histone / genetics. Gene Expression Regulation, Neoplastic / genetics. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15927522.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / centromere protein F
  •  go-up   go-down


60. Zhou CX, Gao Y: Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis. Oncol Rep; 2006 Sep;16(3):505-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of beta-catenin, Pin1 and cylin D1 in salivary adenoid cystic carcinoma: relation to tumor proliferation and metastasis.
  • The aims of this study were to investigate the expression levels of beta-catenin, Pin1 and cyclin D1 in salivary adenoid cystic carcinomas (SACC ) and to evaluate its clinical importance, furthermore, to elucidate whether beta-catenin expression was aberrant in SACC and whether Pin1 was involved in aberrant beta-catenin and cyclin D1 expression.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Cyclin D1 / metabolism. Peptidylprolyl Isomerase / metabolism. Salivary Gland Neoplasms / metabolism. beta Catenin / metabolism


61. Andreadis D, Epivatianos A, Mireas G, Nomikos A, Poulopoulos A, Yiotakis J, Barbatis C: Immunohistochemical detection of E-cadherin in certain types of salivary gland tumours. J Laryngol Otol; 2006 Apr;120(4):298-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reduction and/or absence of E-cadherin was only observed in pleomorphic adenoma at the peripheral cells of the duct-like or island structures, or in the cells exhibiting plasmacytoid or stromal differentiation.
  • Furthermore, a weak to moderate loss of expression which was related to tissue tumour subtype was seen in malignant tumours such as: adenoid cystic carcinomas; polymorphous low-grade adenocarcinomas; acinic cell carcinomas; and mucoepidermoid low-grade, epithelial-myoepithelial, lymphoepithelial and squamous low-grade carcinomas.
  • Moderate to extreme loss or alternative cytoplasmic non-functional expression were observed in cases of salivary ductal carcinoma, carcinosarcoma, myoepithelial carcinoma, oncocytic adenocarcinoma, unspecified adenocarcinoma and squamous high-grade carcinomas.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoma, Adenoid Cystic / chemistry. Carcinoma, Ductal / chemistry. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adenolymphoma / chemistry. Adenoma / chemistry. Adenoma, Pleomorphic / chemistry. Humans. Immunohistochemistry / methods. Salivary Gland Diseases / metabolism. Salivary Glands / chemistry

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623973.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins
  •  go-up   go-down


62. Du ZZ, Ren H, Zhang CJ, Song JF, Liang YP, Zheng M, Deng M: [Surgical treatment of primary malignant tumors of the trachea and main bronchus]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):152-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical management included sleeve tracheal resection in 8 cases, lower trachea and carina resection with carina reconstruction in 4 cases, local enucleation of the tumor in 4 cases, left or right carino-pneumonectomy and carina reconstruction in 2 cases, and resection of the tracheal or bronchial tumor and reconstruction of the airway under cardiopulmonary bypass in 6 cases.
  • RESULTS: Among the 18 cases, there were 7 adenoid cystic carcinomas, 9 squamous cell carcinomas, 1 lymphoepithelial-like carcinoma and 1 follicular non-Hodgkin lymphoma.
  • All the cases recovered well except one who died of endotracheal bleeding and asphyxia at the 10(th) postoperative day.
  • [MeSH-major] Bronchial Neoplasms / surgery. Carcinoma, Adenoid Cystic / surgery. Carcinoma, Squamous Cell / surgery. Tracheal Neoplasms / surgery. Tracheotomy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538896.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Jensen AD, Nikoghosyan A, Windemuth-Kieselbach C, Debus J, Münter MW: Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC. BMC Cancer; 2010 Oct 11;10:546
Hazardous Substances Data Bank. CARBON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High local control rates in adenoid cystic carcinomas could be achieved by highly conformal radiotherapy techniques and particle (neutron/carbon ion) therapy.
  • METHODS/DESIGN: The COSMIC trial is a prospective, mono-centric, phase II trial evaluating toxicity (primary endpoint: mucositis ≥ CTCAE°3) and efficacy (secondary endpoint: local control, disease-free survival) in the combined treatment with IMRT and carbon ion boost in 54 patients with histologically proved (≥R1-resected, inoperable or Pn+) salivary gland malignancies.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Radiother Oncol. 2001 May;59(2):161-7 [11325445.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):391-8 [12738314.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Sep;129(9):944-8 [12975266.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40 [14751537.001]
  • [Cites] Head Neck. 2004 Feb;26(2):154-62 [14762884.001]
  • [Cites] Head Neck. 2004 Aug;26(8):681-92; discussion 692-3 [15287035.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):358-64 [15380567.001]
  • [Cites] Head Neck Surg. 1986 Jan-Feb;8(3):177-84 [3744850.001]
  • [Cites] Cancer. 1994 May 15;73(10):2563-9 [8174054.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11 [15629600.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1278-82 [15995521.001]
  • [Cites] Cancer. 2005 Jul 15;104(2):338-44 [15937907.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):152-9 [16904520.001]
  • [Cites] Radiat Oncol. 2006;1:17 [16756669.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1242-9 [17116822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):982-7 [17241753.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):410-4 [18374509.001]
  • (PMID = 20937120.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01154270
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 7440-44-0 / Carbon
  • [Other-IDs] NLM/ PMC2958954
  •  go-up   go-down


64. Seethala RR, LiVolsi VA, Zhang PJ, Pasha TL, Baloch ZW: Comparison of p63 and p73 expression in benign and malignant salivary gland lesions. Head Neck; 2005 Aug;27(8):696-702
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sectioned formalin-fixed paraffin-embedded tissue cut at 3 mum was immunostained with antibodies that recognize all isozymes of p63 and p73 and evaluated with respect to percentage of positive cells and localization.
  • A significant difference between p63 and p73 positivity was only seen in adenoid cystic carcinomas (p = .006).

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley Periodicals, Inc.
  • (PMID = 16021638.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


65. Takeda S, Hashimoto T, Kusu T, Kawamura T, Nojiri T, Funakoshi Y, Kadota Y, Maeda H: Management and surgical resection for tracheobronchial tumors institutional experience with 12 patients. Interact Cardiovasc Thorac Surg; 2007 Aug;6(4):484-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the records of 12 patients with primary tracheobronchial tumors and various clinical characteristics treated at our institution to investigate our overall management experience with disease.
  • Over a 21-year period, we treated 1405 cases of primary pulmonary neoplasms, of which 12 (0.9%) patients had primary tracheobronchial tumors with eight different histological types, including three adenoid cystic carcinomas, two bronchial carcinoids, two papillomas, one squamous cell carcinoma, one mucous gland adenoma, one inflammatory pseudotumor, one schwannoma, and one mucoepidermoid carcinoma.
  • [MeSH-major] Bronchial Neoplasms / surgery. Lung Neoplasms / surgery. Tracheal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17669912.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Cavalcante RB, Lopes FF, Ferreira AS, Freitas Rde A, de Souza LB: Immunohistochemical expression of vimentin, calponin and HHF-35 in salivary gland tumors. Braz Dent J; 2007;18(3):192-7
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The cells predominantly stained by all tested antibodies included nonluminal cells in duct-like and tubular structures, such as those seen in pleomorphic adenomas and adenoid cystic carcinomas, as well as cells in the cords and nests of polymorphous low-grade adenocarcinomas and peripheral cells of sheets and nests of myoepitheliomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Adenoid Cystic / metabolism. Muscle Proteins / metabolism. Myoepithelioma / metabolism. Salivary Gland Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176708.001).
  • [ISSN] 1806-4760
  • [Journal-full-title] Brazilian dental journal
  • [ISO-abbreviation] Braz Dent J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Microfilament Proteins; 0 / Muscle Proteins; 0 / Vimentin; 0 / calponin
  •  go-up   go-down


67. Cardoso SV, Souza KC, Faria PR, Eisenberg AL, Dias FL, Loyola AM: Assessment of angiogenesis by CD105 antigen in epithelial salivary gland neoplasms with diverse metastatic behavior. BMC Cancer; 2009;9:391
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: CD105 positive vessels were absent in normal salivary gland tissue, were rare in pleomorphic adenomas and adenoid cystic carcinomas (ACC), more common in polymorphous low-grade adenocarcinomas and highest in mucoepidermoid carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Jul 20;19(31):3449-59 [10918603.001]
  • [Cites] BMC Cancer. 2009;9:72 [19250538.001]
  • [Cites] Head Neck. 2002 Aug;24(8):779-83 [12203804.001]
  • [Cites] FASEB J. 2003 Jun;17(9):984-92 [12773481.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):248-53 [12819391.001]
  • [Cites] World J Gastroenterol. 2003 Jul;9(7):1604-6 [12854174.001]
  • [Cites] Trends Cardiovasc Med. 2003 Oct;13(7):301-7 [14522471.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6557-63 [14528280.001]
  • [Cites] J Biol Chem. 1992 Sep 25;267(27):19027-30 [1326540.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):856-61 [10029075.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Virchows Arch. 2006 Jun;448(6):768-75 [16612622.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):861-6 [16784986.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Jul;10(3):249-60 [16807804.001]
  • [Cites] J Surg Oncol. 2006 Oct 1;94(5):413-7 [16967447.001]
  • [Cites] Pathol Int. 2006 Dec;56(12):717-23 [17096728.001]
  • [Cites] BMC Cancer. 2007;7:95 [17543095.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):489-502 [17717633.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):453-67 [17828470.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):340-4 [18008358.001]
  • [Cites] Virchows Arch. 2008 Oct;453(4):359-67 [18795324.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1091-103 [18987874.001]
  • [Cites] Eur J Cancer. 2002 Aug;38(12):1564-79 [12142044.001]
  • (PMID = 19889225.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / ENG protein, human; 0 / Receptors, Cell Surface
  • [Other-IDs] NLM/ PMC2777937
  •  go-up   go-down


68. Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, Licitra L, Pilotti S: TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma. Transl Oncol; 2008 Sep;1(3):121-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.
  • Salivary duct carcinomas (SDCs) and adenoid cystic carcinomas (ACCs) are the most aggressive and the most frequent carcinomas of the salivary glands, respectively.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncol Rep. 2001 May-Jun;8(3):477-84 [11295066.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2237-45 [11489797.001]
  • [Cites] Prostate. 2000 Oct 1;45(2):140-8 [11027413.001]
  • [Cites] Cancer Lett. 2000 Jun 1;154(1):107-11 [10799746.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5388-94 [10681513.001]
  • [Cites] J Laryngol Otol. 2009 Feb;123(2):250-2 [18405406.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Am J Surg Pathol. 2007 Nov;31(11):1683-94 [18059225.001]
  • [Cites] Head Neck. 2007 Oct;29(10):907-12 [17563907.001]
  • [Cites] Histopathology. 2007 Jul;51(1):114-5 [17532773.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Oral Oncol. 2007 Jan;43(1):33-6 [16757202.001]
  • [Cites] J Oral Maxillofac Surg. 2006 Apr;64(4):636-41 [16546643.001]
  • [Cites] Cancer Lett. 2006 Jan 28;232(1):90-8 [16242838.001]
  • [Cites] Oral Oncol. 2005 Oct;41(9):934-9 [16054424.001]
  • [Cites] Oncogene. 2005 Jul 28;24(32):5108-18 [15870692.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8214-9 [15623596.001]
  • [Cites] Invest New Drugs. 2005 Jan;23(1):31-7 [15528978.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] Int J Biol Markers. 1999 Apr-Jun;14(2):68-72 [10399625.001]
  • [Cites] Clin Cancer Res. 1998 Aug;4(8):1887-98 [9717816.001]
  • [Cites] Prostate. 1998 Aug 1;36(3):172-80 [9687989.001]
  • [Cites] Int J Cancer. 1999 May 5;81(3):417-27 [10209957.001]
  • [Cites] J Craniomaxillofac Surg. 1997 Dec;25(6):328-34 [9504310.001]
  • [Cites] Ann Anat. 1998 Apr;180(2):157-63 [9587639.001]
  • [Cites] Hum Pathol. 1996 Jun;27(6):561-6 [8666365.001]
  • [Cites] Head Neck. 1997 Mar;19(2):126-33 [9059870.001]
  • [Cites] Cancer Res. 1994 Nov 1;54(21):5675-82 [7522962.001]
  • [Cites] J Histochem Cytochem. 1994 Nov;42(11):1417-25 [7523489.001]
  • [Cites] Science. 1987 Jan 9;235(4785):177-82 [3798106.001]
  • [Cites] Mol Cell Biol. 1989 Jan;9(1):24-33 [2927393.001]
  • [Cites] J Urol. 2004 Oct;172(4 Pt 1):1545 [15371892.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):294-9 [15236194.001]
  • [Cites] Histopathology. 2004 Mar;44(3):301-2 [14987238.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):938-43 [14871970.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4132-8 [14519636.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5592-601 [12944907.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jul;80(2):207-14 [12908824.001]
  • [Cites] Mol Cancer Ther. 2003 May;2(5):471-8 [12748309.001]
  • [Cites] Histopathology. 2003 Apr;42(4):348-56 [12653946.001]
  • [Cites] Nature. 2003 Feb 13;421(6924):756-60 [12610629.001]
  • [Cites] Hum Pathol. 2002 May;33(5):484-95 [12094373.001]
  • [Cites] Lancet Oncol. 2002 Mar;3(3):137-44 [11902499.001]
  • [Cites] Pathol Res Pract. 2001;197(9):621-6 [11569926.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1238-43 [11106082.001]
  • (PMID = 18795122.001).
  • [ISSN] 1936-5233
  • [Journal-full-title] Translational oncology
  • [ISO-abbreviation] Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2533140
  •  go-up   go-down


69. Llorente JL, Nazar G, Cabanillas R, Fernández de León R, Suárez C: Subtemporal-preauricular approach in the management of infratemporal and nasopharyngeal tumours. J Otolaryngol; 2006 Jun;35(3):173-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 19 benign lesions and 21 malignant tumours, the most common being nasopharyngeal carcinomas, juvenile angiofibromas, and adenoid-cystic carcinomas.
  • All 19 patients with benign tumours are alive, although 5 of them (26%) presented with residual or recurrent disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929993.001).
  • [ISSN] 0381-6605
  • [Journal-full-title] The Journal of otolaryngology
  • [ISO-abbreviation] J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


70. Constantinidou A, Jones RL, Reis-Filho JS: Beyond triple-negative breast cancer: the need to define new subtypes. Expert Rev Anticancer Ther; 2010 Aug;10(8):1197-213
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond triple-negative breast cancer: the need to define new subtypes.
  • Advances in the systemic treatment of early breast cancer have led to significant improvements in survival for patients with hormone receptor- and/or HER2-positive disease.
  • These tumors, however, encompass a wide range of subtypes with varying prognosis, including a number of special types with a good prognosis (e.g., adenoid cystic carcinomas and secretory carcinoma).
  • Understanding the molecular underpinning of distinct subgroups of these cancers is crucial for the identification of novel therapeutic targets and individualization of treatment for patients with triple-negative disease.


71. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM: Does altered fractionation influence the risk of radiation-induced optic neuropathy? Int J Radiat Oncol Biol Phys; 2005 Jul 15;62(4):1070-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: Between 1964 and 2000, 273 patients with tumors of the nasopharynx, paranasal sinuses, nasal cavity, and hard palate adenoid cystic carcinomas were treated with curative intent and had radiation fields that included the optic nerves and/or chiasm.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15990010.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


72. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 13 expression in salivary gland tumors. Int J Biol Markers; 2006 Apr-Jun;21(2):106-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas (ACC), polymorphous low grade adenocarcinomas (PLGA), acinic cell carcinomas (ACI), mucoepidermoid carcinomas (MEC) and adenocarcinomas not otherwise specified (ANOS) of both minor and major salivary glands were examined.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Adenoid Cystic / metabolism. Gene Expression Regulation, Neoplastic. Kallikreins / biosynthesis. Mouth Mucosa / metabolism. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Humans. Immunohistochemistry. Prognosis. Salivary Glands / metabolism

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16847813.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK13 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


73. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 8 expression in salivary gland tumors. Head Neck Pathol; 2008 Sep;2(3):169-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human kallikrein 8 protein (KLK8) is expressed in many normal tissues including esophagus, skin, testis, tonsil, kidney, breast, and salivary gland, and is found in biological fluids including breast milk, amniotic fluid, seminal fluid and serum.
  • It has also been shown to be a biomarker and prognostic factor for breast cancer.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas NOS of both minor and major salivary glands were examined.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma, Pleomorphic / metabolism. Kallikreins / metabolism. Salivary Gland Neoplasms / metabolism. Salivary Glands, Minor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Humans. Immunoenzyme Techniques

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2006 Mar;54(3):337-42 [16286664.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):167-72 [14710225.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1153-9 [15138549.001]
  • [Cites] Mol Cancer Res. 2004 May;2(5):257-80 [15192120.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 3;85(3):200-6 [8423624.001]
  • [Cites] Gene. 1998 Jun 15;213(1-2):9-16 [9714609.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Clin Chem. 1999 Jun;45(6 Pt 1):790-9 [10351987.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Cancer Lett. 2005 Jun 16;224(1):1-22 [15911097.001]
  • [Cites] FEBS Lett. 2005 Dec 19;579(30):6879-84 [16337200.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1487-93 [16533772.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):643-52 [16800725.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):653-63 [16800726.001]
  • [Cites] Biol Chem. 2006 Jun;387(6):723-31 [16800733.001]
  • [Cites] Int J Biol Markers. 2006 Apr-Jun;21(2):106-10 [16847813.001]
  • [Cites] Tumour Biol. 2006;27(5):274-82 [16888409.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11763-70 [17178872.001]
  • [Cites] Int J Biol Markers. 2006 Oct-Dec;21(4):201-5 [17177156.001]
  • [Cites] Clin Chim Acta. 2007 May;381(1):78-84 [17382920.001]
  • [Cites] J Biol Chem. 2007 Nov 2;282(44):31852-64 [17823117.001]
  • [Cites] Biochim Biophys Acta. 2007 Sep;1776(1):22-31 [17629406.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):7-18 [16897430.001]
  • [Cites] Trends Endocrinol Metab. 2000 Mar;11(2):54-60 [10675891.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):806-11 [11309326.001]
  • [Cites] Expert Rev Mol Diagn. 2001 Jul;1(2):182-90 [11901813.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1198-205 [12142373.001]
  • [Cites] Biol Chem. 2002 Jul-Aug;383(7-8):1045-57 [12437087.001]
  • [Cites] Clin Chem. 2003 Jan;49(1):87-96 [12507964.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jan;190(1):60-6 [14749636.001]
  • (PMID = 20614312.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / KLK8 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2807567
  • [Keywords] NOTNLM ; Human kallikrein 8 / Immunohistochemistry / Kallikreins / Prognostic markers / Salivary gland tumors
  •  go-up   go-down


74. Strianese D, Baldi G, Staibano S, Baldi A, De Rosa G, Tranfa F, Bonavolontà G: Expression of apoptosis-related markers in malignant epithelial tumours of the lacrimal gland and their relation to clinical outcome. Br J Ophthalmol; 2007 Sep;91(9):1239-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological diagnosis was re-examined and blocks selected were evaluated for the following parameters: incidence of apoptosis with TUNEL assay, expression of p53 and Bcl-2 using monoclonal antibody.
  • RESULTS: Re-eximination of the 21 specimens was as follow: 11 adenoid cystic carcinomas, 4 mucoepidermoid carcinomas, 3 squamous cell carcinomas and 3 adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1993 Apr 29;362(6423):786-7 [8479514.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):133-8 [8055477.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] J Pathol. 1994 Jan;172(1):1-4 [7931821.001]
  • [Cites] Nature. 1995 Apr 20;374(6524):670 [7715717.001]
  • [Cites] Semin Cancer Biol. 1995 Feb;6(1):17-25 [7548837.001]
  • [Cites] Diagn Mol Pathol. 1995 Dec;4(4):235-8 [8634778.001]
  • [Cites] Br J Cancer. 1997;75(4):537-41 [9052406.001]
  • [Cites] Br J Cancer. 1997;75(8):1185-94 [9099968.001]
  • [Cites] Ophthalmology. 1997 Oct;104(10):1622-5 [9331201.001]
  • [Cites] Histopathology. 1998 Jan;32(1):28-34 [9522213.001]
  • [Cites] Arch Ophthalmol. 1998 May;116(5):613-6 [9596497.001]
  • [Cites] J Pathol. 1999 Jan;187(1):127-37 [10341713.001]
  • [Cites] Ann Diagn Pathol. 1999 Aug;3(4):199-204 [10459045.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):164-8 [10647736.001]
  • [Cites] Eur J Neurosci. 2000 Jul;12(7):2281-90 [10947807.001]
  • [Cites] Pathol Int. 2000 Aug;50(8):603-9 [10972857.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):651-8 [11237386.001]
  • [Cites] Am J Ophthalmol. 1971 Jan;71(1 Pt 2):178-92 [5542123.001]
  • [Cites] Br J Ophthalmol. 1979 Sep;63(9):600-6 [486378.001]
  • [Cites] Can J Ophthalmol. 1982 Feb;17(1):3-9 [6282425.001]
  • [Cites] Ophthalmology. 1989 Apr;96(4):431-5 [2726173.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):401-7 [1320924.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • (PMID = 17431014.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1954920
  •  go-up   go-down


75. Darling MR, Tsai S, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 3 (prostate specific antigen) and human kallikrein 5 expression in salivary gland tumors. Int J Biol Markers; 2006 Oct-Dec;21(4):201-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human kallikrein 5 protein (hK5) is expressed in many normal tissues, most notably in skin, breast, salivary gland and esophagus.
  • It has also been shown to be a potential biomarker for breast, ovarian and testicular cancer.
  • Human kallikrein 3 (hK3; prostate-specific antigen) is the most useful marker for adenocarcinoma of the prostate gland.
  • Pleomorphic adenomas, adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.

  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17177156.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.- / Kallikreins; EC 3.4.21.- / kallikrein 5, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


76. Darling MR, Jackson-Boeters L, Daley TD, Diamandis EP: Human kallikrein 6 expression in salivary gland tumors. J Histochem Cytochem; 2006 Mar;54(3):337-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas (PA), adenoid cystic carcinomas, polymorphous low-grade adenocarcinomas, acinic cell carcinomas, mucoepidermoid carcinomas, and adenocarcinomas not otherwise specified of both minor and major salivary glands were examined.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286664.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


77. Emanuel P, Wang B, Wu M, Burstein DE: p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma. Mod Pathol; 2005 May;18(5):645-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 Immunohistochemistry in the distinction of adenoid cystic carcinoma from basaloid squamous cell carcinoma.
  • Morphologic distinction of high-grade adenoid cystic carcinoma from basaloid squamous cell carcinoma can be difficult.
  • Archival, routinely processed slides were subjected to citrate-based antigen retrieval, exposure to anti-p63 monoclonal 4A4, and developed with a streptavidin-biotin kit and diaminobenzidine as chromogen. p63 was detected in 100% of the adenoid cystic carcinomas (n=14) and 100% of basaloid squamous cell carcinomas (n=16).
  • Basaloid squamous cell carcinomas consistently displayed diffuse p63 positivity, with staining of nearly 100% of tumor cells.
  • In contrast, adenoid cystic carcinoma displayed a consistently compartmentalized pattern within tumor nests.
  • (1) selective staining of a single peripheral layer of p63-positive cells surrounding centrally located tumor cells that were p63-negative and (2) tumor nests consisting of multiple contiguous glandular/cribriform-like units of p63-positive cells surrounding or interspersed with p63-negative cells. p63 immunostaining constitutes a specific and accurate means of distinguishing adenoid cystic carcinoma from basaloid squamous cell carcinoma. p63 positivity in adenoid cystic carcinoma appears to be homologous to that seen in the basal and/or myoepithelial compartments of salivary gland and other epithelia, and may signify a stem-cell-like role for these peripheral cells.
  • Diffuse p63 positivity in basaloid squamous cell carcinoma suggests dysregulation of p63-positive stem cells in poorly differentiated squamous carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Phosphoproteins / analysis. Trans-Activators / analysis
  • [MeSH-minor] DNA-Binding Proteins. Diagnosis, Differential. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Transcription Factors. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15529180.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


78. Boitte JP, Traoré J, Boukhet F, Mondié JM, Traoré M, Delbosc B: [Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old girl]. J Fr Ophtalmol; 2006 Oct;29(8):937-40
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenoid cystic carcinoma of the lacrimal gland in a 14-year-old girl].
  • [Transliterated title] Carcinome adénoïde kystique de la glande lacrymale chez une enfant âgée de 14 ans.
  • The discovery of unilateral exophthalmia requires multidisciplinary care made all the more difficult in the case of a 14-year-old girl living in a tropical environment.
  • The child, C.A., resident of the town of Djenné in Mali, was examined for nonpulsate, nonretractile, left lateral unilateral exophthalmia, painful upon palpation of a left upper-external mass under the orbital rim.
  • The diagnosis was cylindroma, or adenoid cystic carcinoma.
  • Cylindromas or adenoid cystic carcinomas of the lachrymal gland are the second most common cause of epithelial tumors in this gland, which are characterized by a high degree of malignancy, a very high rate of recurrence, and a low survival rate at 5 years.
  • [MeSH-major] Carcinoma, Adenoid Cystic. Eye Neoplasms. Lacrimal Apparatus

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075512.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


79. Sasahira T, Oue N, Kirita T, Luo Y, Bhawal UK, Fujii K, Yasui W, Kuniyasu H: Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland. Histopathology; 2008 Dec;53(6):667-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reg IV expression is associated with cell growth and prognosis of adenoid cystic carcinoma in the salivary gland.
  • The aim was to examine Reg IV expression in adenoid cystic carcinomas (ACCs) in salivary glands.
  • Reg IV expression was found in 41% (17/41) of ACCs, but in none of 40 oral squamous cell carcinomas (OSCCs) and was associated with nodal metastasis (P = 0.047) and poor prognosis (P = 0.012) in ACCs.
  • CONCLUSIONS: These results suggest that Reg IV might accelerate cell growth and disease progression of ACCs.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Lectins, C-Type / metabolism. Salivary Gland Neoplasms / pathology. Salivary Glands / pathology
  • [MeSH-minor] Aged. Cell Line, Tumor. Cell Proliferation. Disease Progression. Disease-Free Survival. Humans. Immunohistochemistry. Mucin-2 / metabolism. Phosphorylation. Prognosis. Receptor, Epidermal Growth Factor / metabolism


80. Aubry MC, Heinrich MC, Molina J, Lewis JE, Yang P, Cassivi SD, Corless CL: Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer; 2007 Dec 1;110(11):2507-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenoid cystic carcinoma of the lung: absence of KIT mutations.
  • BACKGROUND: Primary pulmonary adenoid cystic carcinomas (ACCs) are rare lung neoplasms that are challenging to completely resect and can exhibit poor survival.
  • Adjuvant therapy is often ineffective and identification of a targeted novel therapy would be useful.
  • METHODS: Primary salivary gland-type tumors of the lung diagnosed between 1972 and 2002 at the Mayo Clinic were identified and the subset of primary pulmonary ACCs were reviewed.
  • The majority of ACC cases were predominantly the cribriform type (74.4%).
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Lung Neoplasms / metabolism. Mutation. Proto-Oncogene Proteins c-kit / genetics. Proto-Oncogene Proteins c-kit / metabolism

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17932891.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


81. Yu Y, Zhang R, Dai C: [The study on the en bloc resection of the external auditory canal to treat external auditory canal carcinoma in the early stage]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Apr;23(7):313-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The study on the en bloc resection of the external auditory canal to treat external auditory canal carcinoma in the early stage].
  • To improve early diagnosis and the effective surgical management of external auditory canal carcinoma.
  • METHOD: Twelve cases of the early stage external auditory canal carcinoma were reviewed retrospectively.
  • Postoperative pathological diagnosis revealed that 6 cases with adenoid cystic carcinomas, 5 cases of squamous cell carcinomas, 1 case of cerumenal adenocarcinoma.
  • Five cases of squamous cell carcinomas, 1 case of cerumenal adenocarcinoma and 3 cases of adenoid cystic carcinomas received radiotherapy postoperatively.
  • All patients were alive free of carcinoma during the follow-up.
  • CONCLUSION: Timely and accurate biopsy is the key point to diagnose the early stage external auditory canal carcinoma.
  • The complete resection with safety margin of external auditory canal carcinoma can improve the effect of surgery.
  • [MeSH-major] Carcinoma / surgery. Ear Neoplasms / surgery. Ear, External / surgery. Otologic Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19670611.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


82. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, Jordan RC: Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia; 2010 Sep;12(9):708-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands.
  • This study reports an opposite finding: we have found strong evidence that the MAPK pathway is inhibited in a subset of adenoid cystic carcinomas (ACCs) of the salivary glands.
  • Because ACC seems to proliferate despite inactivation of the c-Kit signaling pathway, we suggest that selective inhibition of c-Kit is probably not a suitable treatment strategy for ACC.

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31 [18568040.001]
  • [Cites] Hum Mol Genet. 2008 Feb 1;17(3):419-30 [17981815.001]
  • [Cites] PLoS One. 2009;4(6):e6040 [19557180.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):157-62 [10655061.001]
  • [Cites] Genes Dev. 2000 Feb 1;14(3):301-12 [10673502.001]
  • [Cites] Blood. 2002 Mar 1;99(5):1741-4 [11861291.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S52-9 [12528773.001]
  • [Cites] Science. 2003 Jan 31;299(5607):708-10 [12522257.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4572-81 [12458225.001]
  • [Cites] Am J Med Genet A. 2003 Oct 1;122A(2):125-32 [12955764.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1224-31 [14681323.001]
  • [Cites] Cell. 2004 Mar 19;116(6):855-67 [15035987.001]
  • [Cites] Science. 2004 Apr 23;304(5670):554 [15016963.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):37-42 [15108803.001]
  • [Cites] Head Neck. 2004 Sep;26(9):829-31 [15350030.001]
  • [Cites] J Mol Graph Model. 2004 Oct;23(2):139-52 [15363456.001]
  • [Cites] Am J Surg. 1974 Oct;128(4):512-20 [4371368.001]
  • [Cites] Nature. 1986 Apr 3-9;320(6061):415-21 [3007997.001]
  • [Cites] EMBO J. 1987 Nov;6(11):3341-51 [2448137.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Mol Cell Biol. 1988 Jun;8(6):2472-8 [3043178.001]
  • [Cites] Nature. 1988 Sep 1;335(6185):88-9 [2457811.001]
  • [Cites] Nucleic Acids Res. 1988 Aug 25;16(16):7773-82 [3047672.001]
  • [Cites] Cell. 1988 Oct 7;55(1):185-92 [2458842.001]
  • [Cites] Cell. 1990 Oct 5;63(1):203-11 [2208279.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8696-9 [1717985.001]
  • [Cites] Cell. 1993 Jul 30;74(2):395-404 [8343963.001]
  • [Cites] Blood. 1996 Aug 15;88(4):1225-33 [8695840.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10248-53 [9092574.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Med Genet. 1998 Jan 6;75(1):101-3 [9450866.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Oncogene. 1999 Sep 30;18(40):5546-53 [10523831.001]
  • [Cites] Mod Pathol. 1999 Oct;12(10):956-60 [10530560.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):585-90 [15659505.001]
  • [Cites] Leukemia. 2005 Feb;19(2):310-2 [15538400.001]
  • [Cites] Anticancer Drugs. 2005 Aug;16(7):719-26 [16027519.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6271-3; author reply 6273-4 [16135502.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Nat Rev Cancer. 2006 Aug;6(8):593-602 [16862190.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:461-7 [16869784.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):988-94 [17234357.001]
  • [Cites] Lab Invest. 2007 Apr;87(4):365-71 [17259998.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):75-83 [18980290.001]
  • (PMID = 20824047.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NIDCR NIH HHS / DE / T32 DE017249; United States / NIDCR NIH HHS / DE / 1T32DE019096; United States / NCI NIH HHS / CA / U10 CA21661; United States / NIDCR NIH HHS / DE / T32 DE019096; United States / NCI NIH HHS / CA / U10 CA021661; United States / NIDCR NIH HHS / DE / DE017249-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2933691
  •  go-up   go-down


83. Schwarz S, Ettl T, Kleinsasser N, Hartmann A, Reichert TE, Driemel O: Loss of Maspin expression is a negative prognostic factor in common salivary gland tumors. Oral Oncol; 2008 Jun;44(6):563-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of the study was to analyze Maspin expression in salivary gland cancer as well as its prognostic impact on survival in comparison to clinical parameters.
  • High proportions of Maspin expression were observed in adenoid cystic carcinomas, mucoepidermoid carcinomas and carcinomas ex pleomorphic adenoma, low proportions were seen in salivary duct carcinomas.
  • Acinic cell carcinomas did not show any Maspin expression.
  • Analysis of the prognostic impact of Maspin expression was restricted to salivary gland carcinoma types of intermediate malignancy grade (adenoid cystic carcinoma, mucoepidermoid carcinoma and carcinoma ex pleomorphic adenoma).
  • According to these findings, Maspin might be useful as a new prognostic marker in adenoid cystic carcinoma and in salivary gland carcinomas with intermediate grade of malignancy where grading systems are still under debate.
  • [MeSH-major] Carcinoma, Mucoepidermoid / metabolism. Salivary Gland Neoplasms / metabolism. Serpins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / mortality. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / mortality. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Prognosis. Serine Proteinase Inhibitors / pharmacology. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17936671.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


84. Kruse AL, Grätz KW, Obwegeser JA, Lübbers HT: Malignant minor salivary gland tumors: a retrospective study of 27 cases. Oral Maxillofac Surg; 2010 Dec;14(4):203-9
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 27 minor salivary gland carcinomas, 48.1% were adenoid cystic carcinomas (ACC), 29.7% mucoepidermoid carcinomas (MEC), 22.2% adenocarcinomas (ADCA).
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / secondary. Adult. Age Factors. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / epidemiology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / epidemiology. Carcinoma, Mucoepidermoid / secondary. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / epidemiology. Oral Ulcer / epidemiology. Palatal Neoplasms / epidemiology. Radiotherapy, Adjuvant / statistics & numerical data. Retrospective Studies. Survival Rate. Switzerland / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20369266.001).
  • [ISSN] 1865-1569
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


85. He JF, Ge MH, Zhu X, Chen C, Tan Z, Li YN, Gu ZY: Expression of RUNX3 in salivary adenoid cystic carcinoma: implications for tumor progression and prognosis. Cancer Sci; 2008 Jul;99(7):1334-40
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of RUNX3 in salivary adenoid cystic carcinoma: implications for tumor progression and prognosis.
  • Runt-related transcription factor-3 (RUNX3), being a tumor suppressor gene in gastric cancer, plays an important role in inhibiting cellular growth by participating in the transforming growth factor-beta-dependent apoptosis.
  • The aim of this study was to determine the expression of RUNX3 in normal salivary glands and adenoid cystic carcinomas (ACCs), comparing the results with clinicopathological factors and patient survival.
  • [MeSH-major] Carcinoma, Adenoid Cystic / chemistry. Core Binding Factor Alpha 3 Subunit / analysis. Salivary Gland Neoplasms / chemistry
  • [MeSH-minor] Blotting, Western. Cytoplasm / chemistry. Disease Progression. Humans. Immunohistochemistry. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Salivary Glands / chemistry. Transforming Growth Factor beta / pharmacology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410404.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 3 Subunit; 0 / Runx3 protein, human; 0 / Transforming Growth Factor beta
  •  go-up   go-down


86. Maruya S, Shirasaki T, Nagaki T, Kakehata S, Kurotaki H, Mizukami H, Shinkawa H: Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications. BMC Cancer; 2009;9:72
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of topoisomerase IIalpha protein in salivary gland carcinomas: histogenetic and prognostic implications.
  • BACKGROUND: Salivary gland carcinomas are relatively uncommon heterogeneous malignancies characterized by locoregional invasion and distant metastasis.
  • METHODS: The protein expression of topoIIalpha was evaluated immunohistochemically in formalin-fixed, paraffin-embedded tissue from 54 salivary gland carcinomas and 20 benign tumors (10 pleomorphic adenomas and 10 Warthin's tumors).
  • The primary salivary gland carcinoma specimens consisted of 17 adenoid cystic carcinomas, 7 adenocarcinomas not otherwise specified, 7 mucoepidermoid carcinomas, 6 salivary duct carcinomas, 3 acinic cell carcinomas, 3 carcinomas ex pleomorphic adenomas, 3 epithelial-myoepithelial carcinomas, 2 carcinosarcomas, 2 lymphoepithelial carcinomas, 2 myoepithelial carcinomas, 1 oncocytic carcinoma, and 1 squamous cell carcinoma.
  • RESULTS: Of the 54 primary salivary gland carcinomas, 38 (70%) showed positive expression (> or = 10%) of topoIIalpha protein, and 16 carcinomas (30%) and all benign tumors were negative (p < 0.001).
  • Expression of topoIIalpha was more frequently observed in salivary duct carcinoma, carcinoma ex pleomorphic adenoma, adenocarcinoma, and adenoid cystic carcinoma, solid type, and it was associated with advanced stage and shortened survival.
  • Furthermore, it may provide useful prognostic information and suggests the potential efficacy of topoIIalpha-targeting therapy in patients with salivary gland carcinoma.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Salivary Gland Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / enzymology. Carcinoma, Adenoid Cystic / pathology. Child. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2000 Aug;22(5):489-97 [10897109.001]
  • [Cites] Head Neck. 2008 May;30(5):680-3 [17972317.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1061-7 [11948114.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1107-16 [12006526.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40 [12042765.001]
  • [Cites] Lancet Oncol. 2002 Apr;3(4):235-43 [12067686.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Jan-Feb;65(1):26-32 [12624503.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Clin Cancer Res. 2003 Oct 15;9(13):4682-8 [14581337.001]
  • [Cites] Int J Oncol. 2004 Jan;24(1):201-9 [14654958.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5A):3965-70 [14666704.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):944-6 [14871971.001]
  • [Cites] J Otolaryngol. 2003 Oct;32(5):328-31 [14974865.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):637-45 [15044918.001]
  • [Cites] Arch Otolaryngol. 1984 Mar;110(3):172-6 [6322732.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):1062-9 [6088017.001]
  • [Cites] Oncology (Williston Park). 1998 May;12(5):671-80; discussion 683 [9597678.001]
  • [Cites] Pathol Res Pract. 2005;200(11-12):791-9 [15792122.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R374-84 [15987433.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2673-8 [16763282.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):64-77 [17113234.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):735-41 [17113340.001]
  • [Cites] Head Neck. 2007 Nov;29(11):1002-9 [17427971.001]
  • [Cites] Hum Pathol. 2001 Jun;32(6):596-604 [11431714.001]
  • (PMID = 19250538.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Other-IDs] NLM/ PMC2654461
  •  go-up   go-down


87. Persson M, Andrén Y, Mark J, Horlings HM, Persson F, Stenman G: Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci U S A; 2009 Nov 3;106(44):18740-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck.
  • Here we describe a new mechanism of activation of MYB in human cancer involving gene fusion.
  • We show that the t(6;9)(q22-23;p23-24) translocation in adenoid cystic carcinomas (ACC) of the breast and head and neck consistently results in fusions encoding chimeric transcripts predominantly consisting of MYB exon 14 linked to the last coding exon(s) of NFIB.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / pathology. Head and Neck Neoplasms / genetics. Head and Neck Neoplasms / pathology. Oncogene Proteins, Fusion / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 1995 Oct;15(10):5552-62 [7565707.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Jun;10(2):115-21 [7520264.001]
  • [Cites] Oncogene. 1998 Feb 19;16(7):865-72 [9484777.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3017-33 [10378697.001]
  • [Cites] Eur J Oral Sci. 2004 Dec;112(6):545-7 [15560839.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1375-84 [15608679.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):224-35 [15826837.001]
  • [Cites] Genes Chromosomes Cancer. 2006 May;45(5):470-81 [16444749.001]
  • [Cites] Oral Oncol. 2006 Nov;42(10):994-1004 [16762588.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1025-30 [17437991.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Cell. 2007 Oct 5;131(1):146-59 [17923094.001]
  • [Cites] Oncogene. 2008 May 8;27(21):3072-80 [18059337.001]
  • [Cites] Nat Rev Cancer. 2008 Jul;8(7):523-34 [18574464.001]
  • [Cites] Mol Biol Evol. 2008 Oct;25(10):2189-98 [18667440.001]
  • [Cites] Blood. 2009 Jan 15;113(3):505-16 [18818396.001]
  • [Cites] PLoS One. 2009;4(6):e6040 [19557180.001]
  • [Cites] Cancer Biol Ther. 2008 Nov;7(11):1758-64 [18708755.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1315-23 [12368205.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D552-6 [14681479.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5758-62 [2668947.001]
  • [Cites] Oncogene. 1989 Dec;4(12):1419-23 [2687764.001]
  • [Cites] Genes Dev. 1992 Dec;6(12B):2524-35 [1340467.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2278-90 [8139533.001]
  • [Cites] Genomics. 1995 Jul 1;28(1):66-73 [7590749.001]
  • (PMID = 19841262.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ FJ969915/ FJ969916/ FJ969917
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYB-NFIB fusion protein, human; 0 / MicroRNAs; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2773970
  •  go-up   go-down


88. Ahn Y, Chang H, Lim YS, Hah JH, Kwon TK, Sung MW, Kim KH: Primary tracheal tumors: review of 37 cases. J Thorac Oncol; 2009 May;4(5):635-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Except the papilloma cases (n = 3), all of them were managed successfully without recurrence.
  • Squamous cell carcinomas (n = 11) and adenoid cystic carcinomas (n = 9) comprised most of the malignant tumors.
  • Five-year overall survival rate was 41.1% for squamous cell carcinoma and 45.7% for adenoid cystic carcinoma and no statistically significant difference (p = 0.673) was observed.
  • Among malignant tumors, surgery should be considered as the first choice of treatment, regardless of the histologic type, if the tumors are resectable.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Carcinoma, Squamous Cell / pathology. Papilloma / pathology. Tracheal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357541.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Tirado Y, Williams MD, Hanna EY, Kaye FJ, Batsakis JG, El-Naggar AK: CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior. Genes Chromosomes Cancer; 2007 Jul;46(7):708-15
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CRTC1/MAML2 fusion transcript in high grade mucoepidermoid carcinomas of salivary and thyroid glands and Warthin's tumors: implications for histogenesis and biologic behavior.
  • We analyzed 55 primary salivary gland tumors including 22 mucoepidermoid carcinomas (MECs) to determine the association of MECT1/TORC1/CRTC1-MAML2 fusion transcript to tumor types, level of MEC differentiation and clinicopathologic parameters.
  • Our primary salivary gland tumors were composed of 22 MECs, 11 Warthin's tumors, 10 adenoid cystic carcinomas, two basaloid carcinomas, five salivary duct carcinomas, and five adenocarcinomas, not otherwise specified.
  • None of the 22 primary non-MEC gland salivary carcinomas were positive for the transcript.
  • [MeSH-major] Adenolymphoma / genetics. Carcinoma, Mucoepidermoid / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. RNA, Messenger / genetics. Salivary Gland Neoplasms / genetics. Thyroid Neoplasms / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437281.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CRTC1 protein, human; 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / MAML2 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / Transcription Factors
  •  go-up   go-down


90. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LF, de Jong D, Van de Vijver MJ, Van't Veer LJ, Peterse JL: Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol; 2008 Oct;216(2):141-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Refinement of breast cancer classification by molecular characterization of histological special types.
  • Most invasive breast cancers are classified as invasive ductal carcinoma not otherwise specified (IDC NOS), whereas about 25% are defined as histological 'special types'.
  • These special-type breast cancers are categorized into at least 17 discrete pathological entities; however, whether these also constitute discrete molecular entities remains to be determined.
  • Current therapy decision-making is increasingly governed by the molecular classification of breast cancer (luminal, basal-like, HER2+).
  • The molecular classification is derived from mainly IDC NOS and it is unknown whether this classification applies to all histological subtypes.
  • We aimed to refine the breast cancer classification systems by analysing a series of 11 histological special types [invasive lobular carcinoma (ILC), tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant cells, micropapillary, adenoid cystic, metaplastic, and medullary carcinoma] using immunohistochemistry and genome-wide gene expression profiling.
  • Hierarchical clustering analysis confirmed that some histological special types constitute discrete entities, such as micropapillary carcinoma, but also revealed that others, including tubular and lobular carcinoma, are very similar at the transcriptome level.
  • When classified by expression profiling, IDC NOS and ILC contain all molecular breast cancer types (ie luminal, basal-like, HER2+), whereas histological special-type cancers, apart from apocrine carcinoma, are homogeneous and only belong to one molecular subtype.
  • Our analysis also revealed that some special types associated with a good prognosis, such as medullary and adenoid cystic carcinomas, display a poor prognosis basal-like transcriptome, providing strong circumstantial evidence that basal-like cancers constitute a heterogeneous group.
  • Taken together, our results imply that the correct classification of breast cancers of special histological type will allow a more accurate prognostication of breast cancer patients and facilitate the identification of optimal therapeutic strategies.
  • [MeSH-major] Breast Neoplasms / classification. Carcinoma, Ductal, Breast / classification. Gene Expression Regulation, Neoplastic


91. Bhatia KS, Rasalkar DD, Lee YP, Wong KT, King AD, Yuen HY, Ahuja AT: Evaluation of real-time qualitative sonoelastography of focal lesions in the parotid and submandibular glands: applications and limitations. Eur Radiol; 2010 Aug;20(8):1958-64
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This was correlated with diagnosis from aspiration cytology or histology.
  • RESULTS: There were 29 Warthin's tumours (WTs), 23 pleomorphic adenomas (PAs), 2 adenoid cystic carcinomas, 1 adenosquamous carcinoma, 1 nodal metastasis from nasopharyngeal carcinoma, 1 lymphoma (2 deposits), 3 Kuttner tumours and 4 cases of Kimura's disease.
  • CONCLUSION: These preliminary findings suggest that qualitative real-time ultrasound elastography, although an ancillary technique to conventional ultrasound in the salivary glands, is likely to have a poor ability to discriminate benign lesions (particularly PAs) from malignant disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20407904.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


92. Zhang S, Bao R, Bagby J, Abreo F: Fine needle aspiration of salivary glands: 5-year experience from a single academic center. Acta Cytol; 2009 Jul-Aug;53(4):375-82
MedlinePlus Health Information. consumer health - Salivary Gland Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A total of 191 salivary gland FNAs were performed at Louisiana State University Health Science Center from 2003 to 2007, and all were done on major salivary glands except for 1 case.
  • There were 5 false negatives: 2 adenoid cystic carcinomas, 1 acinic cell carcinoma, 1 polymorphous low grade adenocarcinoma and 1 metastatic basaloid squamous cell carcinoma.
  • The only false positive was a pleomorphic adenoma misdiagnosed as adenoid cystic carcinoma.
  • Five benign neoplasms were interpreted as reactive processes, including 2 Warthin's tumors, 2 sebaceous lymphoadenomas and 1 pleomorphic adenoma.
  • CONCLUSION: Our results are consistent with the literature that salivary gland FNA has good sensitivity, specificity and accuracy in the diagnosis of salivary neoplasms.

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697720.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Maruya SI, Myers JN, Weber RS, Rosenthal DI, Lotan R, El-Naggar AK: ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion! Oral Oncol; 2005 Jul;41(6):580-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICAM-5 (telencephalin) gene expression in head and neck squamous carcinoma tumorigenesis and perineural invasion!
  • To determine the association of this gene in tumorigenesis and perineural invasion, we analyzed the expression and functional status of ICAM-5 mRNA transcripts in 30 different human cancer cell lines and 25 head and neck squamous carcinoma specimens by reverse-transcriptase polymerase chain reaction (cell lines and specimens) and in vitro functional assays (cell lines).
  • ICAM-5 transcripts were detected in 28 (93%) of 30 cell lines derived from primary head and neck, colon, thyroid, cervical, pancreatic, skin, and adenoid cystic carcinomas.
  • In tissue specimens, none of the 25 histologically normal oral mucosal specimens had detectable ICAM-5 level, whereas 16 (64%) of the 25 matched primary squamous carcinomas showed expression.
  • Carcinoma specimens high ICAM-5 expression had a high incidence of perineural invasion.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Head and Neck Neoplasms / metabolism. Membrane Glycoproteins / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975520.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / ICAM5 protein, human; 0 / Membrane Glycoproteins; 0 / Morpholines; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / RNA, Small Interfering; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases
  •  go-up   go-down


94. Mäkitie AA, Pintor Dos Reis P, Arora S, Macmillan C, Warner GC, Sukhai M, Dardick I, Perez-Ordonez B, Wells R, Brown D, Gilbert R, Freeman J, Gullane P, Irish J, Kamel-Reid S: Molecular characterization of salivary gland malignancy using the Smgb-Tag transgenic mouse model. Lab Invest; 2005 Aug;85(8):947-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In order to identify genetic changes that occur during the development of invasive adenocarcinoma from normal salivary gland, we used the Smgb-Tag transgenic mouse model.
  • This transgene induces the progressive development of dysplasia to invasive adenocarcinoma in the submandibular salivary gland.
  • Gene expression patterns from 20 submandibular glands (two normal, nine dysplasia and nine adenocarcinoma samples) were assessed using a mouse 15 K cDNA array.
  • Further analysis identified 25 significantly overexpressed and 28 underexpressed cDNA sequences in adenocarcinoma as compared to dysplasia.
  • Immunohistochemical analysis was used to validate the expression of Ptn and Cd24a at the protein level in a subset of 16 mouse salivary glands (four normal, five dysplasia and seven adenocarcinoma samples), as well as in 23 human submandibular gland tumors (16 pleomorphic adenomas, three adenoid cystic carcinomas, one acinic cell carcinoma, one adenocarcinoma NOS, one myoepithelial and one mucoepidermoid carcinoma).
  • [MeSH-major] Adenocarcinoma / genetics. Disease Models, Animal. Salivary Gland Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15880136.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Weigelt B, Geyer FC, Reis-Filho JS: Histological types of breast cancer: how special are they? Mol Oncol; 2010 Jun;4(3):192-208
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological types of breast cancer: how special are they?
  • Breast cancer is a heterogeneous disease, comprising multiple entities associated with distinctive histological and biological features, clinical presentations and behaviours and responses to therapy.
  • Microarray-based technologies have unravelled the molecular underpinning of several characteristics of breast cancer, including metastatic propensity and histological grade, and have led to the identification of prognostic and predictive gene expression signatures.
  • Furthermore, a molecular taxonomy of breast cancer based on transcriptomic analysis has been proposed.
  • However, microarray studies have primarily focused on invasive ductal carcinomas of no special type.
  • Owing to the relative rarity of special types of breast cancer, information about the biology and clinical behaviour of breast cancers conveyed by histological type has not been taken into account.
  • Histological special types of breast cancer account for up to 25% of all invasive breast cancers.
  • For instance, secretory carcinomas of the breast consistently harbour the t(12;15) translocation that leads to the formation of the ETV6-NTRK3 fusion gene, adenoid cystic carcinomas consistently display the t(6;9) MYB-NFIB translocation and lobular carcinomas consistently show inactivation of the CDH1 gene through multiple molecular mechanisms.
  • Furthermore, histopathological and molecular analysis of tumours from conditional mouse models has provided direct evidence for the causative role of specific genes in the genesis of specific histological special types of breast cancer.
  • Here we review the associations between the molecular taxonomy of breast cancer and histological special types, discuss the possible origins of the heterogeneity of breast cancer and propose an approach for the identification of novel therapeutic targets based on the study of histological special types of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Pathol. 2006 Aug;209(4):445-53 [16739104.001]
  • [Cites] Cancer Res. 1997 Oct 1;57(19):4360-7 [9331099.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Jan;24(1):72-7 [9892111.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4636-44 [16651414.001]
  • [Cites] J Pathol. 2010 Jan;220(2):307-15 [19921711.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Mod Pathol. 2009 Nov;22(11):1401-14 [19633645.001]
  • [Cites] Genome Biol. 2007;8(5):R76 [17493263.001]
  • [Cites] Nat Med. 2009 Aug;15(8):842-4 [19661985.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1805(1):105-17 [19931353.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6652-62 [17121884.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):628-31 [12152162.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] Hum Pathol. 1986 Mar;17(3):212-5 [2419235.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2523-36 [15034139.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] J Pathol. 2009 Sep;219(1):131-40 [19562735.001]
  • [Cites] EMBO Mol Med. 2009 Sep;1(6-7):315-22 [20049735.001]
  • [Cites] Histopathology. 2008 Jan;52(1):58-66 [18171417.001]
  • [Cites] Biochim Biophys Acta. 2009 Dec;1796(2):201-15 [19406209.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Sep;44(1):103-8 [15887243.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Mod Pathol. 2006 Feb;19(2):264-71 [16341146.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] J Pathol. 2008 Dec;216(4):394-8 [18798222.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1160-7 [19204204.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18740-4 [19841262.001]
  • [Cites] J Pathol. 2005 Jan;205(2):248-54 [15641021.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]
  • [Cites] Nature. 2002 Jan 31;415(6871):530-6 [11823860.001]
  • [Cites] Breast Cancer Res Treat. 2010 Feb;120(1):95-109 [19350388.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R23 [17397528.001]
  • [Cites] BMC Genomics. 2006 Apr 27;7:96 [16643655.001]
  • [Cites] J Natl Cancer Inst. 1975 Aug;55(2):231-73 [169369.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4038-44 [18593979.001]
  • [Cites] Mod Pathol. 2005 Dec;18(12):1623-31 [16258515.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):209-29 [20537966.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] J Pathol. 2008 Aug;215(4):398-410 [18484683.001]
  • [Cites] Breast Cancer Res. 2008;10(4):R65 [18662380.001]
  • [Cites] Breast Cancer Res Treat. 2007 Apr;102(2):143-55 [16906480.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Oncogene. 2006 Sep 25;25(43):5846-53 [16998499.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):944-51 [18413808.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] N Y State J Med. 1973 May 1;73(9):1078-82 [4348806.001]
  • [Cites] Oncologist. 2006 Sep;11(8):868-77 [16951390.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] J Pathol. 2004 Oct;204(2):131-9 [15376261.001]
  • [Cites] Oncogene. 2007 Dec 13;26(57):7859-71 [17603561.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2568-81 [18487574.001]
  • [Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]
  • [Cites] Cancer Res. 2009 May 15;69(10 ):4116-24 [19435916.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jun;40(2):152-7 [15101049.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4660-71 [15897907.001]
  • [Cites] Nat Rev Clin Oncol. 2009 Dec;6(12):718-30 [19942925.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] J Pathol. 2010 Apr;220(5):562-73 [20099298.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3153-8 [18490649.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):605-13 [16469754.001]
  • [Cites] J Pathol. 2010 Jan;220(2):263-80 [19927298.001]
  • [Cites] N Engl J Med. 2009 Jun 25;360(26):2719-29 [19516027.001]
  • [Cites] J Pathol. 2010 Jan;220(1):45-57 [19877120.001]
  • [Cites] J Clin Oncol. 2010 Mar 1;28(7):1145-53 [20100965.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3785-90 [18591545.001]
  • [Cites] Lancet Oncol. 2010 Apr;11(4):339-49 [20181526.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):255-66 [20434415.001]
  • [Cites] Lancet Oncol. 2009 Nov;10(11):1070-6 [19801202.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2711-22 [19318498.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Histopathology. 2008 Jun;52(7):840-6 [18462362.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):734-46 [15897740.001]
  • [Cites] J Pathol. 2008 Oct;216(2):141-50 [18720457.001]
  • [Cites] Nat Rev Cancer. 2007 Sep;7(9):659-72 [17721431.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Nature. 2009 Oct 8;461(7265):809-13 [19812674.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):128-34 [19132008.001]
  • [Cites] Cancer Invest. 2008 Feb;26(1):1-10 [18181038.001]
  • [Cites] Ann Oncol. 2009 Nov;20(11):1763-70 [19602565.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] J Clin Pathol. 2005 Jul;58(7):700-4 [15976335.001]
  • [Cites] Oncogene. 2008 Sep 11;27(40):5359-72 [18490921.001]
  • [Cites] Oncogene. 2006 Jun 29;25(28):3994-4008 [16491124.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11565-75 [18089785.001]
  • [Cites] Histopathology. 1992 Jun;20(6):479-89 [1607149.001]
  • [Cites] Breast Cancer Res Treat. 2008 Sep;111(1):121-7 [17929165.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] J Pathol. 2009 Jan;217(2):229-41 [19009588.001]
  • [Cites] Breast Cancer Res. 2005;7(4):143-8 [15987465.001]
  • [Cites] Histopathology. 2008 Jan;52(1):108-18 [18171422.001]
  • [Cites] Lancet. 2005 Feb 19-25;365(9460):671-9 [15721472.001]
  • [Cites] Breast Cancer Res Treat. 2009 Sep;117(2):273-80 [18815879.001]
  • [Cites] Mod Pathol. 2009 Feb;22(2):291-8 [19011601.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Dec;23(4):300-6 [9824202.001]
  • [Cites] J Pathol. 2007 Mar;211(4):389-98 [17212342.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3155-63 [17975657.001]
  • [Cites] J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45 [9701363.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Carcinogenesis. 2005 Apr;26(4):703-11 [15459022.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):347-53 [15725803.001]
  • [Cites] Nature. 2009 Dec 24;462(7276):1005-10 [20033038.001]
  • [Cites] Histopathology. 2006 Jul;49(1):10-21 [16842242.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2310-8 [11981002.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12111-6 [17626182.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):790-800 [19228622.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):127-35 [17330844.001]
  • [Cites] Breast Cancer Res. 2007;9(2):R24 [17417968.001]
  • [Cites] Pathobiology. 2008;75(2):119-31 [18544967.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7167-75 [14612510.001]
  • [Cites] Med Hypotheses. 2001 Nov;57(5):655-66 [11735329.001]
  • [Cites] J Natl Cancer Inst. 1973 May;50(5):1111-8 [4123242.001]
  • [Cites] J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5 [14519755.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1077-83 [10706127.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 21;99(22):1683-94 [18000219.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):2085-94 [20179196.001]
  • [Cites] Mol Oncol. 2010 Jun;4(3):192-208 [20452298.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 [16478745.001]
  • [Cites] J Clin Oncol. 2010 Jan 1;28(1):99-104 [19917872.001]
  • [Cites] Histopathology. 1995 Sep;27(3):219-26 [8522285.001]
  • [Cites] J Clin Pathol. 2010 Jun;63(6):492-6 [18552174.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nat Med. 2009 Aug;15(8):907-13 [19648928.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):791-9 [17851544.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):663-71 [19147582.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):437-49 [17097565.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):917-21 [15829967.001]
  • [Cites] Oncogene. 2007 Mar 29;26(14):2126-32 [17016441.001]
  • [Cites] J Pathol. 2009 Jul;218(3):301-15 [19479727.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Clin Pathol. 2008 Sep;61(9):1045-50 [18641405.001]
  • [Cites] J Pathol. 2005 Nov;207(3):260-8 [16167361.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10292-301 [17079448.001]
  • [Cites] Breast Cancer Res. 2009;11 Suppl 3:S12 [20030863.001]
  • [Cites] J Clin Pathol. 2009 Jul;62(7):604-12 [19561229.001]
  • [Cites] Histopathology. 2006 Jul;49(1):22-34 [16842243.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Int J Cancer. 2001 May 1;92(3):404-8 [11291078.001]
  • [Cites] Clin Cancer Res. 2007 Jan 1;13(1):90-101 [17200343.001]
  • [Cites] Int J Surg Pathol. 2009 Aug;17(4):285-302 [19103611.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jul;110(2):245-56 [17912630.001]
  • (PMID = 20452298.001).
  • [ISSN] 1878-0261
  • [Journal-full-title] Molecular oncology
  • [ISO-abbreviation] Mol Oncol
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


96. Shigeishi H, Yoneda S, Taki M, Nobumori T, Ohta K, Higashikawa K, Yasui W, Kamata N: Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors. Oncol Rep; 2006 Apr;15(4):933-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We examined the expression of Bub1 mRNA and protein in 21 human salivary gland tumors (7 pleomorphic adenomas, 2 warthin tumors, 5 mucoepidermoid carcinomas, 3 adenoid cystic carcinomas and 4 acinic cell carcinomas) and 3 normal submandibular glands using real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR) or western blotting.
  • [MeSH-minor] Adenolymphoma / genetics. Adenolymphoma / metabolism. Adenolymphoma / pathology. Adenoma, Pleomorphic / genetics. Adenoma, Pleomorphic / metabolism. Adenoma, Pleomorphic / pathology. Blotting, Western. Carcinoma, Acinar Cell / genetics. Carcinoma, Acinar Cell / metabolism. Carcinoma, Acinar Cell / pathology. Carcinoma, Adenoid Cystic / genetics. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Mucoepidermoid / genetics. Carcinoma, Mucoepidermoid / metabolism. Carcinoma, Mucoepidermoid / pathology. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Neoplasm Staging. Proliferating Cell Nuclear Antigen / analysis. Protein-Serine-Threonine Kinases. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16525682.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / RNA, Messenger; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / BUB1 protein, human; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


97. Muller A, Sonkoly E, Eulert C, Gerber PA, Kubitza R, Schirlau K, Franken-Kunkel P, Poremba C, Snyderman C, Klotz LO, Ruzicka T, Bier H, Zlotnik A, Whiteside TL, Homey B, Hoffmann TK: Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy. Int J Cancer; 2006 May 1;118(9):2147-57
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptors in head and neck cancer: association with metastatic spread and regulation during chemotherapy.
  • Head and neck carcinomas are histologically and clinically heterogeneous.
  • While squamous cell carcinomas (SCC) are characterized by lymphogenous spread, adenoid cystic carcinomas (ACC) disseminate preferentially hematogenously.
  • To study cellular and molecular mechanisms of organ-specific metastasis, we used SCC and ACC cell lines and tumor tissues, obtained from patients with primary or metastatic disease.
  • Furthermore, CXCL12 suppressed the rate of apoptosis induced by cisplatin in ACC cells, suggesting that signaling via CXCR4 may be part of a tumor cell survival program.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Squamous Cell / secondary. Cisplatin / pharmacology. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Receptors, Chemokine / analysis


98. Iczkowski KA, Montironi R: Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu. J Clin Pathol; 2006 Dec;59(12):1327-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic/basal cell carcinoma of the prostate strongly expresses HER-2/neu.
  • Adenoid cystic/basal cell carcinoma (ACBCC) is a rare neoplasm in the prostate.
  • The HER-2/neu (c-erbB-2) gene has been reportedly overexpressed in adenoid cystic carcinomas in other organs, but its status in prostatic ACBCC was uncertain.
  • Protein and mRNA expression were 2+ to 3+ (of 3+) in all patients with ACBCC, compared to a breast cancer control with strong reactivity, whereas protein expression was noted in only one acinar carcinoma and mRNA expression was absent in all acinar carcinomas.
  • The finding of strong, consistent HER-2/neu expression in ACBCC suggests that treatment with Herceptin (trastuzumab) may be effective in patients with this rare tumour.
  • [MeSH-major] Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Basal Cell / metabolism. Mixed Tumor, Malignant / metabolism. Prostatic Neoplasms / metabolism. Receptor, ErbB-2 / metabolism


99. Snaathorst J, Sewnaik A, Paridaens D, de Krijger RR, van der Meij EH: Primary epithelial tumors of the lacrimal gland; a retrospective analysis of 22 patients. Int J Oral Maxillofac Surg; 2009 Jul;38(7):751-7
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All benign tumors were pleomorphic adenomas; 50% of the malignant neoplasms were adenoid cystic carcinomas.
  • The mean time from complaint to diagnosis was 3 years for benign tumors and 6 months for malignancies.
  • 33% of patients with malignancy died of their disease.
  • They have a long duration of symptoms before diagnosis, are treated by limited surgery and recur infrequently.
  • Malignant tumors have a short duration of symptoms, are sometimes mistaken for inflammatory disease, and are, even in case of aggressive surgery, characterized by a high rate of local recurrence and metastasis.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369032.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


100. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK: Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res; 2006 Dec 15;12(24):7353-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Implications of methylation patterns of cancer genes in salivary gland tumors.
  • Methylation occurred in 33 of 79 (41.8%) malignant tumors; 8 (30.8%) adenoid cystic carcinomas, 6 (33.3%) mucoepidermoid carcinomas, 6 (42.9%) acinic cell carcinomas, and 13 (62.0%) salivary duct carcinomas.
  • RASSF1 and RARbeta2 represented 75.8% of methylation events occurring most frequently in salivary duct and acinic cell carcinomas.
  • (b) high-grade carcinomas were significantly methylated compared with low-grade phenotypes;.
  • [MeSH-major] Carcinoma / metabolism. DNA Methylation. Salivary Gland Neoplasms / genetics. Salivary Gland Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / metabolism. Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Carcinoma, Acinar Cell / metabolism. Carcinoma, Adenoid Cystic / metabolism. Carcinoma, Mucoepidermoid / metabolism. Child. DNA Modification Methylases. DNA Repair Enzymes. Death-Associated Protein Kinases. Female. Gene Expression Regulation, Neoplastic. Genes, Neoplasm. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Receptors, Retinoic Acid / metabolism. Tumor Suppressor Protein p14ARF / metabolism. Tumor Suppressor Proteins / metabolism

  • Genetic Alliance. consumer health - Salivary Gland Cancer.
  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189407.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Neoplasm Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Protein p14ARF; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down






Advertisement